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ABSTRACT (150 words) 40 
Expression of the EVI1 proto-oncogene is deregulated by chromosomal translocations 41 
in some cases of acute myeloid leukemia (AML) and is associated with poor clinical 42 
outcome. Here, through transcriptomic and metabolomic profiling of hematopoietic cells, 43 
we reveal that EVI1 overexpression alters cellular metabolism.  A pooled shRNA screen 44 
identified the ATP-buffering, mitochondrial creatine kinase CKMT1 as a metabolic 45 
dependency in EVI1-positive AML. EVI1 promotes CKMT1 expression by repressing the 46 
myeloid differentiation regulator RUNX1. Suppression of arginine-creatine metabolism 47 
by CKMT1-directed shRNAs or by the small molecule cyclocreatine selectively 48 
decreased the viability, promoted cell cycle arrest and apoptosis of human EVI1-positive 49 
AML cells, and prolonged survival in human orthotopic and mouse primary AML models. 50 
CKMT1 inhibition alters mitochondrial respiration and ATP production, an effect that is 51 
abrogated by phospho-creatine-mediated reactivation of the arginine-creatine pathway. 52 
Targeting CKMT1 is a promising therapeutic strategy for this EVI1-driven AML subtype 53 
that is highly resistant to current treatment regimens. 54 
 55 
56 
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INTRODUCTION 57 
Recent investigations into the relationship between cancer and cellular 58 
metabolism have revealed the strong dependency of different cancers on a diverse 59 
array of metabolic pathways. Therefore, identifying mechanisms by which these 60 
metabolic pathways become deregulated in the first place en route to, or as a result of, 61 
the development of cancer has emerged as a major area of therapeutic and biological 62 
interest. 63 
Deregulation of metabolic pathways can occur through multiple mechanisms, 64 
including alterations in the cellular landscape brought about by mutations in metabolic 65 
enzymes (e.g., IDH1/IDH2 and SDH)1-4. IDH1 and IDH2 mutations, which are initiating 66 
events in high-grade gliomas and frequently occur in acute myeloid leukemia (AML), 67 
interfere with normal IDH1/2 function to produce the pro-oncogenic metabolite R(-)-2-68 
hydroxyglutarate which acts as an epigenetic modulator5-8. Deregulation of metabolic 69 
pathways can also occur through aberrant expression of transcription factors, such as 70 
the proto-oncogene MYC. Transcriptional changes resulting from aberrantly activated 71 
MYC increase glucose uptake and glycolysis in cancer cells and stimulate 72 
glutaminolysis, serine/glycine metabolism, and lipid biosynthesis9. Although MYC and 73 
other transcription factors are typically considered pharmacologically challenging 74 
targets, the diverse metabolic alterations induced by these transcription factors may 75 
constitute another source of unique cancer dependencies and provide multiple 76 
downstream opportunities for therapeutic intervention. It is thus necessary not only to 77 
identify the metabolic changes which occur with cancer development, but to link these 78 
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programs to initiating events and oncogenic drivers; the latter will enable identification of 79 
patient populations that may benefit from specific metabolic interventions. 80 
 81 
Transcriptional modulators are deregulated in AML either by translocation (e.g., 82 
MLL-AF9, AML1-ETO, or PML-RARA) or aberrant expression, as is true of EVI110,11. 83 
Abnormal expression of this transcription factor through chromosome 3q26 84 
rearrangements (e.g., t(3;3)(q21;q26) or inv3(q21;q26)) promotes the development or 85 
progression of high-risk acute myeloid leukemia (AML), for which current treatment 86 
regimens remain inadequate12-15. Here we integrate genomic and metabolic screening 87 
to identify a new druggable metabolic dependency in mouse and human EVI1-positive 88 
AML, including cell lines and primary patient samples. 89 
 90 
RESULTS 91 
EVI1 modulates metabolism in AML cells. 92 
To characterize the transcriptional consequences of EVI1 overexpression in 93 
AML, we generated an EVI1-dependent gene signature from murine bone marrow 94 
LinLow cells infected with a retroviral construct encoding Evi1 (GSE 3472916). We then 95 
used this signature to conduct an open-ended enrichment analysis of 4725 curated 96 
gene sets from the c2 collection assembled from various sources such as online 97 
pathway databases, publications in PubMed, and knowledge of domain experts 98 
available from MSigDB (Figure 1A). We confirmed the findings of other investigators 99 
that gene sets related to cell proliferation and differentiation were enriched in genes 100 
whose expression is suppressed by enforced Evi1 overexpression16-18. Multiple cell 101 
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metabolism-related gene sets were also significantly enriched in an unbiased search of 102 
the complete c2 collection. Evi1 overexpression modulated genes from cellular energy-103 
related pathways, including glycolysis, the TCA cycle, and oxidative phosphorylation, 104 
purine and pyrimidine synthesis, and the metabolism of various amino acids.(Figure 105 
1B). Using an unbiased metabolomic profiling approach, we established that of 292 106 
small metabolites detected by mass spectrometry, steady state levels of 82 were 107 
significantly (-log10 (p value) ≤ 1) changed by Evi1-expression (Supplementary Figure 108 
S1). The most highly enriched metabolic pathways were related to purine and 109 
pyrimidine metabolism, amino acid metabolism (alanine, aspartate, glutamate, arginine, 110 
and proline), the pentose phosphate pathway and glycolysis (Figure 1C). 111 
 112 
To assess whether upregulation of EVI1 in human AML cell lines might promote 113 
oncogenic dependency on metabolic enzymes, we performed an shRNA screen against 114 
67 genes encoding enzymes from glycolysis, the pentose phosphate pathway, the TCA 115 
cycle, and related metabolic pathways in the AML cell lines TF-1 and UCSD-AML1, both 116 
of which express EVI1. These cells were infected with the shRNA library and expanded 117 
until day 36 at which point genomic DNA was harvested and hairpin representation 118 
assessed by sequencing and compared to the representation of the input genomic DNA 119 
at day 0. We identified hairpin sequence that was depleted (hairpins target leukemia-120 
promoting genes) or enriched (hairpins targeting leukemia-suppressing genes) at 36 121 
days compared to the input genomic DNA. These experiments identified 9 depleted and 122 
6 enriched genes overlapping in both lines, tested with at least two hairpins (Figure 1D 123 
and Supplementary Table S1). As expected, three positive control tumor suppressor 124 
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genes, PTEN, TP53 and RB1, scored among the top enriched hits. Three genes of 125 
interest – Ckmt1, Cs, and Sdha genes (murine homologs of human CKMT1, Citrate 126 
Synthase (CS) and Succinate Dehydrogenase Complex, Subunit A (SDHA), 127 
respectively) – were both upregulated by genomic profiling in Evi1-transduced cells and 128 
depleted by multiple shRNAs in the TF-1 and UCSD-AML1 AML cell lines (Figure 1E). 129 
We then infected TF-1 AML cells with multiple hairpins that markedly reduced CKMT1, 130 
SDHA, and CS protein levels (Figure 1F, right panel). While all hairpins significantly 131 
decreased cell growth over a 12-day time course, CKMT1 depletion caused the most 132 
pronounced growth inhibition (Figure 1F). 133 
 134 
CKMT1 is a target in EVI1-positive leukemia. 135 
To address the potential relationship between EVI1 expression and dependence 136 
on CKMT1, we expanded our investigation to a larger panel of human AML cell lines 137 
with and without elevated EVI1 expression. All four EVI1-expressing AML cell lines 138 
exhibited elevated CKMT1 protein expression and activity (Figure 2A and 2B). The 139 
viability of these four cell lines was more strongly decreased compared to all the other 140 
lines tested in response to a treatment with cyclocreatine, an analog of the CKMT1 141 
substrate creatine and inhibitor of the creatine biosynthesis pathway (Figure 2C). 142 
Furthermore, three AML cell lines with elevated EVI1 expression – UT-7, TF-1, and 143 
UCSD-AML1 – exhibited enhanced sensitivity to a reduction in CKMT1 expression 144 
mediated by doxycycline-inducible shRNAs in comparison with the other cell lines 145 
tested (Figure 2D). The human Kasumi-3 cell line was not tested in this experiment due 146 
to its poor transduction efficiency. Similar growth defects were observed with non-147 
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inducible CKMT1-targeting shRNAs (Supplementary Figure S2A and S2B). These 148 
AML cell lines are grown in GM-CSF, and withdrawal of GM-CSF neither affected 149 
CKMT1 expression nor sensitivity of EVI1-expressing cells to cyclocreatine 150 
(Supplementary Figures S2C and S2D). Conversely, GM-CSF supplementation did 151 
not promote CKMT1 expression in the two AML cell lines tested to represent EVI1-null, 152 
CKMT1-null cells: HL-60 and U937 (Supplementary Figures S2E). 153 
 154 
Finally, we assayed EVI1 expression by flow cytometry in a panel of 68 155 
unselected primary AML patient specimens (Figure 2E and Supplementary Table S2). 156 
Samples with at least 5x106 blast cells were subsequently analyzed by flow cytometry 157 
and immunoblot. The four leukemias with the highest levels of EVI1 expression showed 158 
higher CKMT1 protein levels and enhanced sensitivity to cyclocreatine treatment 159 
compared to the leukemias with low EVI1 expression (Figures 2E-2G). Together, these 160 
studies indicate that elevated CKMT1 expression and biochemical dependence on this 161 
metabolic pathway are correlated with high levels of EVI1 expression in both human 162 
AML cell lines and primary patient specimens. 163 
 164 
EVI1 promotes CKMT1 expression through RUNX1 repression. 165 
To clarify how EVI1 regulates cellular CKMT1 expression, we first infected 166 
mouse Linlow, c-kit+ bone marrow cells with either an empty MSCV vector or with a 167 
construct encoding EVI1. Consistent with our analysis of human AMLs, enforced Evi1 168 
expression increased Ckmt1 protein and mRNA levels (Figures 3A and 3B). Moreover, 169 
doxycycline induction of three independent shRNA molecules targeting EVI1 reduced 170 
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CKMT1 expression in TF-1 and UCSD-AML1 cells (Figure 3C). Then, we used a 171 
luciferase reporter system in which the CKMT1 gene promoter was cloned upstream of 172 
a luciferase cassette, and levels of CKMT1 transactivation were assessed using 173 
bioluminescence (Figure 3D). Co-expression of EVI1 and the CKMT1-Luc promoter in 174 
HEK293E cells activated CKMT1 transcription. Deleting a promoter region between -175 
1169 and -943 bp upstream of the transcriptional start site increased basal CKMT1 176 
transactivation at a similar fold-increase to that observed upon EVI1 overexpression. 177 
This effect was recapitulated by deletion of a RUNX1 consensus binding motif ACCACA 178 
(∆ACCACA) from the -1169/-943 CKMT1 promoter sequence (Figure 3E), suggesting 179 
that RUNX1 might repress CKMT1 expression through direct binding to its promoter. In 180 
accordance with this idea, RUNX1 overexpression impeded the capacity of EVI1 to 181 
transactivate CKMT1 (Figure 3F). EVI1 knockdown promoted both an increase in 182 
RUNX1 and a decrease in CKMT1 expression. Furthermore, RUNX1-directed shRNAs, 183 
which abrogated RUNX1 upregulation, prevented a decrease of CKMT1 expression 184 
upon EVI1 knockdown (Figure 3G). 185 
 186 
We then used a ChIP-qPCR approach to dissect the sequential events involved 187 
in EVI1-induced CKMT1 upregulation and the possible role of RUNX1 as an 188 
intermediate in this process (Figure 3H-3L). Multiple red peaks corresponding to EVI1-189 
binding regions appeared on both murine and human RUNX1 gene tracks from two 190 
ChIP-sequencing experiments19,20 (Figure 3H). After immunoprecipitation of Evi1 from 191 
Evi1-overexpressing primary bone marrow murine cells and Runx1 promoter 192 
amplification by qPCR, we found a significant increase in Evi1 binding at the Runx1 193 
9 
 
promoter, accompanied by an increased amount of histone repressive mark H3K27Me3 194 
at the same promoter region (Figure 3I). This was associated with a decrease in the 195 
expression of RUNX1 mRNA and protein levels (Supplementary Figure S3A and 196 
S3B). At basal conditions, Runx1 is bound to Ckmt1 promoter in normal bone marrow 197 
cells. Evi1 overexpression, however, decreased Runx1 binding to the Ckmt1 promoter, 198 
as well as the amount of bound repressive mark H3K27me3, and increased the binding 199 
signal of the transcriptional activation histone mark H3K27Ac (Figure 3J). This was 200 
associated with increased expression of Ckmt1 mRNA and protein levels 201 
(Supplementary Figures S3A and S3B). In contrast, EVI1 knockdown in UCSD-AML1 202 
cells enhanced RUNX1 expression and binding at the CKMT1 promoter (Figure 3K, 203 
and Supplementary Figure S3C and 3D). This led to an increased H3K27Me3 binding 204 
signal and a reduced amount of bound H3K27Ac at the CKMT1 promoter and was 205 
associated with a decreased expression of CKMT1 (Figure 3K). In contrast, 206 
concomitant EVI1 and RUNX1 knockdown decreased repressive H3K27Me3 histone 207 
mark level at the CKMT1 promoter (Figure 3L). Taken together, these results show that 208 
EVI1 represses RUNX1 expression by direct binding to its promoter. This, in turn, 209 
eliminates repressive RUNX1 binding at the CKMT1 promoter and thereby promotes 210 
CKMT1 expression. Moreover, we also observed that RUNX1-directed shRNAs 211 
attenuated by 17-fold (based on the average bioluminescence across the two hairpins) 212 
the reduced disease burden caused by EVI1 depletion (Figure 3M). Finally, we 213 
explored the relationship between EVI1 and RUNX1 expression with CKMT1 mRNA 214 
levels in two AML transcriptional datasets (GSE14468 and GSE10358). We divided 215 
these cohorts into four subgroups: EVI1high/RUNX1low, EVI1high/RUNX1high, 216 
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EVI1low/RUNX1low, and EVI1low/RUNX1high. Consistent with our mechanistic analysis, 217 
AML samples with high CKMT1 levels were significantly more represented within the 218 
EVI1high/RUNX1low subgroup than in the three other subgroups (Figure 3N).  219 
 220 
Creatine kinase activity drives mitochondrial function and ATP production 221 
CKMT1 promotes the metabolism of arginine to creatinine. To determine the 222 
effect of CKMT1 suppression on this pathway, we measured the metabolic flux of 223 
stable-isotope labeled L-arginine 13C6 through creatine synthesis, ornithine / spermine 224 
and ornithine / urea cycle, and the glutamate pathway using mass spectrometry (Figure 225 
4A). As expected, both CKMT1 knockdown and cyclocreatine treatment in UCSD-AML1 226 
and TF-1 cells diminished incorporation of L-Arginine 13C6 into creatinine. Creatinine is 227 
the end metabolite product of the creatine synthesis pathway and is spontaneously 228 
synthesized from phospho-creatine (Figure 4A-C and Supplementary Figure S4A). 229 
We also observed a significant decrease in arginine 13C6 incorporation into the 230 
precursor metabolite of the creatine synthesis pathway, guanidinoacetate, suggesting 231 
an inhibitory feedback loop of end metabolite products on the guanidinoacetate-232 
producing enzyme glycine amidinotransferase, GATM. Of note, cyclocreatine treatment 233 
had a broader effect than shRNA-mediated CKMT1 depletion on arginine metabolism 234 
because it also impaired production of glutamate, α-ketoglutarate, and L-arginino-235 
succinate (Figure 4C). Co-treatment of cells with exogenous phospho-creatine 236 
activated production of guanidinoacetate 13C and creatinine 13C from arginine 13C6 and 237 
thereby rescued cyclocreatine-induced defects on the creatine synthesis pathway alone, 238 
without affecting production of glutamate, α-ketoglutarate, and L-arginino-succinate 239 
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(Figure 4C and Supplementary Figure S4B). Activation of the arginine-creatine 240 
pathway by phospho-creatine prevented the loss of viability of human EVI1-positive 241 
AML cells induced by cyclocreatine or CKMT1-directed shRNAs, and also maintained 242 
the serial replating activity of Evi1-transformed bone marrow cells (Figure 4D-4F).  243 
 244 
We next used a metabolism profiling approach to characterize the effect of CK 245 
pathway alteration on global cell metabolism. Steady state levels of 48 metabolites 246 
highly enriched in pathways related to purine metabolism, amino acid metabolism 247 
(glycine, serine, threonine, arginine, and proline), and energy metabolism (TCA cycle 248 
and glycolysis), were significantly changed by CKMT1 suppression in TF-1 and UCSD-249 
AML1 cells (Figure 4G and 4H). This analysis revealed a significant (p value ≤ 0.05)  250 
decrease in intracellular ATP levels accompanied by an increase in ADP and AMP 251 
levels (Figure 4G). This increase in the ADP/ATP ratio induced by CK pathway 252 
inhibition was only observed in the four AML cell lines expressing high level of CKMT1 – 253 
TF-1, UT-7, UCSD-AML1, and Kasumi-3 – but not in those expressing low levels of 254 
CKMT1 (Figure 4I). Finally, activation of the creatine pathway by phospho-creatine 255 
rescued cyclocreatine-induced decrease in intracellular ATP level, suggesting that the 256 
creatine pathway may regulate ATP production in CKMT1-expressing cells (Figure 4J). 257 
 258 
To investigate this hypothesis, we evaluated the impact of creatine pathway 259 
inhibition on the respiration capacity of the mitochondria, the main organelles involved in 260 
ATP production. Measurement of mitochondrial oxygen consumption rate (OCR) 261 
reflects the capacity to produce ATP. Cyclocreatine treatment decreased basal 262 
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mitochondrial respiration capacity in both TF-1 and UCSD-AML1 cells as well as the 263 
maximal mitochondrial respiration capacity visualized after FCCP supplementation in 264 
UCSD-AML1 cells (Figure 4K). Co-treatment with phospho-creatine counteracted the 265 
effect of cyclocreatine and restored normal mitochondrial respiration capacity, 266 
suggesting that an active creatine pathway is required for promoting mitochondrial 267 
activity. 268 
 269 
Finally, we overexpressed a wild-type (WT) or a metabolically inactive mutant 270 
form of CKMT1 (C316G21) in two AML cell lines, NB-4 and U937, that do not express 271 
endogenous CKMT1 (Supplementary Figure S5A). Wild-type, but not the C316G 272 
mutant form of CKMT1, conferred cyclocreatine sensitivity to these two cell types 273 
(Supplementary Figure S5B), and cyclocreatine treatment significantly reduced ATP 274 
production and basal mitochondrial respiration in cells expressing wild-type CKMT1 275 
(Supplementary Figures S5C and S5D). All together, these data demonstrate that 276 
expression of CKMT1 renders mitochondria dependent on creatine pathway activity for 277 
ATP production. 278 
 279 
Blockade of CK activity diminishes EVI1-expressing cell viability. 280 
To determine the transcriptional consequences of CK pathway inhibition in EVI1-281 
expressing cells, we profiled three EVI1-expressing cell lines, TF-1, UT-7 and UCSD-282 
AML1, treated with cyclocreatine for 24 hours using RNA sequencing (RNAseq). We 283 
identified 54 and 53 genes significantly 1.5-fold upregulated and downregulated, 284 
respectively, compared to control treatment (Figure 5A). An open-ended enrichment 285 
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analysis was next conducted using a relaxed cyclocreatine signature (defined based on 286 
the cut-offs SNR permutation p value ≤ 0.05, Benjamini-Hochberg false discovery rate 287 
(FDR) ≤ 0.05 and absolute fold change for log2 (FPKM) scores ≥ 0.5.) on the entire set 288 
of signatures from the c2 (MsigDB) and DMAP collections (Supplementary Tables S3 289 
and S4). Gene sets related to cell cycle, energy metabolism and cell stemness were 290 
enriched in genes whose expression was suppressed by cyclocreatine and those 291 
related to cell differentiation were more enriched in genes whose downregulation was 292 
induced by both pro-differentiating agents and cyclocreatine. Finally, amino acid 293 
metabolism gene sets were more enriched in genes upregulated by cyclocreatine 294 
(Figure 5B, 5C, and Supplementary Table S5). At the intersection of the three 295 
enriched functional groups – cell cycle, cell stemness, and cell differentiation – a leading 296 
edge analysis isolated a core of ten highly significant genes downregulated by 297 
cyclocreatine treatment in the three lines profiled (Supplementary Figure S6A). We 298 
validated the transcriptional dowregulation of MYC and CCND1 in all of the EVI1-299 
positive cell lines treated with cyclocreatine by real-time PCR (Supplementary Figure 300 
S6B). Cyclocreatine or CKMT1-directed shRNAs increased cell size and cell 301 
vacuolization (Figures 5D-5F). This was accompanied by a G0/G1 cell cycle arrest in 302 
UCSD-AML1 and Kasumi-3 cell lines while TF-1 and UT-7 underwent apoptosis 303 
(Figures 5G and 5H). Finally, expression of the immature cell surface marker CD117 304 
decreased in response to cyclocreatine or CKMT1-direct shRNAs, and this was 305 
associated with inhibition of the serial replating activity of UCSD-AML1, TF-1, and UT-7 306 
cells (Figures 5I and 5J). 307 
 308 
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Progression of EVI1-expressing AML depends on CKMT1 309 
We next sought to investigate whether CKMT1 was required for EVI1-dependent 310 
AML disease development in vivo. Li et al. generated transplantable primary AMLs by 311 
performing retroviral insertional mutagenesis in Mx1-Cre; NrasG12D/+ mice22,23. We 312 
compared two Nras mutant AMLs from this screen: NrasG12D + Evi1 contains a clonal 313 
Evi1 integration and expresses high transcript levels while the control NrasG12D AML 314 
does not. Immunoblot analysis revealed markedly elevated levels of Evi1 and Ckmt1 in 315 
the NrasG12D + Evi1 AML (Figure 6A), and this leukemia was also more sensitive to 316 
inhibition by cyclocreatine treatment than WT or NrasG12D bone marrow cells 317 
(Supplementary Figure S7A). To examine the oncogenic Evi1-dependency on Ckmt1 318 
expression, we transduced NrasG12D and NrasG12D + Evi1 AML cells with a doxycycline-319 
inducible non-targeting control (CT) or two Ckmt1-directed shRNAs. Venus-positive 320 
transduced cells were then sorted and injected into irradiated recipient mice. Once 321 
disease onset was detected, mice were treated with doxycycline to induce hairpin 322 
expression in tandem with an RFP reporter cassette, and knockdown was confirmed by 323 
immunoblot (Figure 6B). Mice transplanted with NrasG12D AML cells transduced with 324 
either control or Ckmt1-directed shRNAs, or NrasG12D + Evi1 AML cells expressing 325 
shControl cells succumbed to aggressive AML with a median latency of approximately 326 
20 days. By contrast, recipients of NRasG12D + Evi1 AML cells expressing either 327 
shCkmt1_2 or shCkmt1_3 exhibited attenuated disease and survived for approximately 328 
40 days (Figure 6C). Splenomegaly and leukocytosis, which reflect the AML disease 329 
burden, were also markedly reduced in mice transplanted with NRasG12D + Evi1 AML 330 
cells expressing either shCkmt1_2 or shCkmt1_3 (Figure 6D), and the splenic 331 
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proportion of Gr-1+/Mac-1+ granulocytes was substantially reduced compared to 332 
NRasG12D + Evi1 shControl mice (Figure 6E). 333 
 334 
While all NrasG12D + Evi1 mice showed a recurrent expansion within the 335 
LinLow/Sca-1-/c-Kit+/CD16/32+/CD34+ GMP compartment in comparison to wild-type 336 
mice, NrasG12D mice exhibited dominant growth of a less immature LinLow/Sca-1-/c-337 
Kit+/CD16/32+/CD34- population (representative examples in Figure 6F). In NrasG12D 338 
mice, Ckmt1 knockdown did not alter the growth of the leukemic population compared 339 
to shControl mice. In recipients transplanted with NrasG12D + Evi1 AML cells, Ckmt1 340 
suppression suppressed the expansion of the RFP+/Venus+ leukemic population from 341 
58% in shControl mice to 2% in shCkmt1 group, thus reducing the overall growth 342 
advantage of the GMP fraction over MEP and CMP populations. To assess the effects 343 
of Ckmt1 deletion on normal hematopoiesis, CD45.2 bone marrow cells infected with 344 
shCT were transplanted into lethally irradiated recipient mice with an equal number of 345 
CD45.1 competitor bone marrow cells infected with Ckmt1-directed shRNAs 346 
(Supplementary Figure S7B). Chimerism was confirmed based on evaluation of the 347 
ratio of CD45.1 to CD45.2 in bone marrow of recipient mice. Reducing Ckmt1 348 
expression did not alter the repopulating potential on normal hematopoietic cells in 349 
competitive transplantation assays, suggesting no toxic effect of Ckmt1 targeting in 350 
normal bone marrow cells (Supplementary Figure S7C). 351 
 352 
Finally, we investigated the effects of either doxycycline-inducible CKMT1-353 
directed shRNAs or cyclocreatine treatment on leukemia development in xenografts of 354 
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EVI1-low U937-Luc and EVI1-high TF-1 CSF2+-Luc human AML cell lines. Leukemia 355 
burden was monitored in recipients treated therapeutically with doxycycline or 356 
cyclocreatine after detectable disease burden was increasing at day 8 in U937 cells and 357 
day 10 in TF-1 cells (Supplementary Figure S7D and S7E). Consistent with our in vivo 358 
analysis of primary murine Nras mutant AMLs, pharmacologic or genetic inhibition of the 359 
CKMT1-dependent pathway blocked disease progression and prolonged the survival of 360 
mice injected with TF-1 cells but not with U937 cells (Figures 6G and 6H). Co-treatment 361 
with phospho-creatine significantly rescued the effects of cyclocreatine in mice injected 362 
with TF-1 but had no effect in the U937 cell leukemia model (Figure 6I). 363 
 364 
DISCUSSION 365 
Here we found that overexpression of the zinc finger transcription factor EVI1 366 
remodeled the metabolic landscape of immature hematopoietic cells, particularly by 367 
impacting cell energy-related pathways, arginine metabolism, and de novo synthesis of 368 
purines and pyrimidines. The broad transcriptional effects of EVI1 overexpression on 369 
these different metabolic pathways are reminiscent of a recent study which identified 370 
glutaminolysis as a critical pathway for T-cell acute lymphoblastic leukemia growth 371 
downstream of the hyperactivated, mutant form of the transcription factor NOTCH1 and 372 
as a key determinant of the response to anti-NOTCH1 therapies24. Other results 373 
suggest that glycolysis is important for MLL-AF9-driven AML maintenance and 374 
progression and that those leukemic cells are more sensitive to the inhibition of aerobic 375 
glycolysis than normal hematopoietic cells25. This supports the idea that the pro-376 
leukemic effects of EVI1 expression in AML may be mediated, at least in part, by 377 
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perturbations of cell metabolism and that targeting these metabolic dependencies may 378 
be promising therapeutic avenues in EVI1-positive leukemias. 379 
 380 
Our results indicate a higher dependency of EVI1-positive leukemias, compared 381 
to other subgroups of AML, on the creatine kinase pathway. Creatine is one of the end 382 
products of the arginine pathway, which is altered upon EVI1 overexpression. In healthy 383 
cells, arginine can be produced by the ornithine-citrulline-arginine cycle. However, 384 
recent investigations identified that the majority of blasts from patients with AML are 385 
deficient in enzymes specialized in promoting this cycle and are therefore strongly 386 
reliant on extracellular arginine availability26,27. This study suggests that a constitutive 387 
blockade of the ornithine-citrulline-arginine cycle would preferentially redirect 388 
transported arginine through other arginine-dependent metabolic pathways such as the 389 
creatine pathway. Interestingly, a mycoplasma-derived enzyme, ADI-PEG 20, that 390 
degrades extracellular arginine and thus prevents intracellular import of arginine 391 
showed good in vitro anti-leukemic efficacy in 19 samples from a cohort of 38 primary 392 
AML patient samples28. From the entire cohort, only one AML sample harbored a 393 
translocation involving EVI1, and this sample was sensitive to ADI-PEG 20. This finding 394 
would be consistent with the dependency of EVI-positive AML on the creatine kinase 395 
pathway and suggests that EVI1-positive patients may also be good responders to a 396 
therapy targeting the import of arginine. 397 
 398 
CKMT1 has two main functions in energy metabolism: it buffers the cellular ATP 399 
pool by maintaining cytosolic concentrations of phospho-creatine for high cellular 400 
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energy demand to regenerate ATP, and it maintains an energy shuttle between sites of 401 
energy supply and sites of energy demand using the easily diffusible creatine29. Our 402 
results showed that CKMT1 directly impacts mitochondrial respiration and ATP 403 
production. This is reminiscent of the role of hexokinases, another class of 404 
mitochondria-coupled enzymes that utilize ATP produced by mitochondria to catalyze 405 
conversion of glucose into glucose-6-phosphate, the first rate-limiting step of 406 
glycolysis30. In turn, the ADP formed from this reaction stimulates mitochondrial 407 
respiration31,32. Similarly, the increase of the creatine/phospho-creatine interconversion 408 
rate subsequent to CKMT1 overexpression seems to regulate mitochondrial respiration 409 
and then influence mitochondrial ATP production. The expression of CKMT1 alone is 410 
sufficient to reprogram mitochondrial activity, suggesting that CKMT1 upregulation itself 411 
may be one of the main contributors to metabolic perturbations that are necessary to 412 
the pro-leukemic effects of EVI1 in AML.  413 
 414 
Although CKMT1 is ubiquitously expressed, several studies have shown that 415 
some cancer types, such as mesotheliomas, small cell lung and brain tumors, 416 
expressed higher CK protein levels which predict higher sensitivity to cyclocreatine33. 417 
Moreover, high CKMT1 expression is a marker of poor prognosis for patients with 418 
breast cancer34. We established that EVI1 promotes CKMT1 expression by direct 419 
repression of the transcription factor RUNX1. A transcriptomic analysis of 269 patients 420 
with AML revealed that those who harbor t(8;21) or t(11q23) alterations exhibit a wild-421 
type RUNX1 signature, while patients bearing del(7q)/7- or inv3/t(3;3) – responsible for 422 
EVI1 overexpression – express a RUNX1 mutation-derived gene expression 423 
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signature35. This corroborates our observation that CKMT1, whose expression is 424 
repressed by RUNX1, is predominantly upregulated in the EVI1-overexpressing 425 
leukemia subgroup. 426 
 427 
The direct targeting of aberrant transcription factors as a therapeutic strategy remains a 428 
significant challenge in cancer therapy. An alternative approach is to target the unique 429 
liabilities engendered by the altered cellular circuitry present in these transcription-factor 430 
driven malignancies. To this end, we have integrated “omic” approaches to identify 431 
CKMT1 as a druggable liability in EVI-positive AML. In considering the clinical 432 
translation of this finding, it is notable that cyclocreatine can be found in marketed 433 
nutritional and sports supplements. In addition, while not specifically for the mechanism 434 
of CKMT1 inhibition, but rather for use as a cell permeable analogue of creatine, 435 
cyclocreatine was granted orphan designation by the European Commission to Pharma 436 
Gateway AB, Sweden, in 2016 for the treatment of creatine deficiency syndromes. 437 
Despite enthusiasm about the likely safety of this molecule for multiple disease 438 
indications, clinical trials testing the safety and efficacy of cyclocreatine, however, will 439 
still need to be conducted. Another path forward for targeting CKMT1 might be the 440 
development of new selective agents targeting this enzyme.  In summary, this study 441 
supports a potential therapeutic avenue for targeting the CK pathway in EVI1-positive 442 
AML, which remains one of the worst outcome subtypes of this disease. 443 
 444 
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ONLINE METHODS 567 
 568 
Plasmids and shRNA Constructs 569 
Empty and Evi GCDN vectors were a kind gift from Drs. Tomohiko Sato and 570 
Mineo Kurokawa (The University of Tokyo, Tōkyō, Japan). Empty and HA-tagged 571 
pHAGE-CMV-CKMT1 and pHAGE-CMV-RUNX1 vectors were generated by enzyme-572 
mediated site-specific recombination between pENTR223-CKMT1 (Harvard PlasmID 573 
database, HsCD00372650) and pENTR223-RUNX1 (Harvard PlasmID database, 574 
HsCD00378663) donor vectors and pHAGE-CMV-HA destination vector (gift from Dr. J. 575 
Wade Harper, Harvard Medical School, Boston, MA, USA).  576 
 577 
shRNA constructs targeting human CKMT1 (shCKMT1_1 and shCKMT1_2), 578 
EVI1 (shEVI1_1, shEVI1_2, shEVI1_4), CS (shCS_1, shCS_2, shCS3), SDHA 579 
(shSDHA_1, shSDHA_2, shSDHA_3), or RUNX1 (shRUNX1_2, shRUNX1_6) – 580 
sequences listed below – were designed by adapting BIOPREDsi small interfering RNA 581 
predictions. shRNAs were cloned into the TRMPVIR retroviral vector36, containing a 582 
miR30 expression cassette, as 116-nt XhoI–EcoRI fragments, which were generated by 583 
amplifying 97-mer oligonucleotides (Invitrogen) using 5′miR30-XhoI 584 
(TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG) and 3′miR30-EcoRI 585 
(ACTTAGAAGAATTCCGAGGCAGTAGGCA) primers and the Vent polymerase kit 586 
(Invitrogen) with the following conditions: 50 μl reaction containing 0.05 ng 587 
oligonucleotide template, 1× Vent buffer, 0.3 mM of each dNTP, 0.8 μM of each primer, 588 
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and 1.25 U Vent polymerase; cycling: 94 °C for 3 min; 35 cycles of 94 °C for 30 s, 54 °C 589 
for 30 s, and 75 °C for 20 s; 75 °C for 5 min. 590 
 591 
 592 
shRNA constructs targeting murine Ckmt1 (shCkmt1_2 and shCkmt1_3) were 593 
purchased from GE Healthcare and were subcloned from the GIPZ vector into the 594 
TRIPZ-Venus lentiviral vector. The TRIPZ-Venus vector was designed by substitution in 595 
the TRIPZ vector (GE Healthcare), of the puromycin resistance cassette for the 596 
sequence encoding the yellow-green fluorescent protein Venus reporter isolated from 597 
the TRMPVIR vector. Non-inducible human CKMT1-directed shRNAs (CKMT1_3 and 598 
CKMT1_4) and murine Ckmt1-directed shRNAs used for the in vivo chimerism assay 599 
were purchased from TransOMIC Technology Inc.  600 
 601 
For virus production, 12 μg of the above plasmids and 6 μg ψ-eco (for retroviral infection 602 
of murine cells), 6 μg pCMV-GAG/POL and pCMV-VSVG (for retroviral infection of 603 
human cells), or 6 μg pCMV8.9 or psPAX2 and pCMV-VSVG (for lentiviral infection of 604 
human and murine cells) packaging vectors were transfected into the 293T packaging 605 
cell line using X-tremeGENE 9 (Roche), and the resulting viral supernatants were 606 
harvested as previously described37. The lentiviral viruses were then concentrated using 607 
PEG-it™ Virus Precipitation Solution (SBI System Biosciences). 608 
Designation Species Accession Number Target Sequence
shCKMT1_1 Homo Sapiens NM_020990.3 ATCACCCGTGTATGATCCTCC
shCKMT1_2 Homo Sapiens NM_020990.3 TTTACTGGCATCTAGATCCGT
shCS_1 Homo Sapiens NM_004077.2 ATCGCGGATCAGTCTTCCTTA
shCS_2 Homo Sapiens NM_004077.2 AAGAACTGATGTTTCATAGAC
shCS_3 Homo Sapiens NM_004077.2 TGTAACAGCTGCACTGAGCTG
shEVI1_1 Homo Sapiens NM_001105077.3|NM_005241.3|NM_001105078.3|NM_004991.3|NM_001163999.1|NM_001164000.1 TTTCTGTGAAGTAAGCATCTT
shEVI1_2 Homo Sapiens NM_001105077.3|NM_005241.3|NM_001105078.3|NM_004991.3|NM_001163999.1|NM_001164000.1 TTGCACTTGATTTGGGTTCTG
shEVI1_4 Homo Sapiens NM_001105077.3|NM_005241.3|NM_001105078.3|NM_004991.3|NM_001163999.1|NM_001164000.1 TTCCAGTTCAGAATGAGGCGA
shRUNX1_2 Homo Sapiens NM_001001890.2|NM_001754.4|NM_001122607.1 TGATCATCTAGTTTCTGCCGAT
shRUNX1_6 Homo Sapiens NM_001001890.2|NM_001754.4|NM_001122607.1 TCCACTGTGATTTTGATGGCTC
shSDHA_1 Homo Sapiens NM_004168.2 CAGATGCCCTCTTGTTCCCAT
shSDHA_2 Homo Sapiens NM_004168.2 ATGACTCTTCGATGCTCAGGG
shSDHA_3 Homo Sapiens NM_004168.2 AACAGTGTTCTTTGCTCTTAT
shControl AGGAATTATAATGCTTATCTA
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Pooled shRNA Screening 609 
A custom library of 361 hairpins directed against 67 human genes involved in glycolysis, 610 
pentose phosphate pathway, TCA cycle, and related metabolic pathways with at least 3 611 
hairpins per gene, was cloned into a retroviral pMLP2.1 vector and was purchased from 612 
TransOMIC Technology Inc. To preserve library complexity, a minimum of 1000-fold 613 
coverage of the shRNA library was maintained at each step of the screen. Two series of 614 
quadruplicates, from TF-1 and UCSD-AML1 cells, were spin-infected using plates 615 
coated with 10 μg/mL retronectin (Takara) per the manufacturer’s instructions. Fresh 616 
viral supernatant was added onto each retronectin-coated well before spinning for two 617 
hours at 2000g at 32°C to allow virus binding to the retronectin. 7.5×106 cells in 6 mL 618 
transplant media containing 5 μg/mL polybrene (Sigma) and 7.5 mM HEPES buffer 619 
(Sigma) were then seeded into each of these wells and centrifuged for 1 hour at 1800g 620 
to promote cell transduction. The final transduction rate estimated was between 5% and 621 
10% of GFP-positive cells. Cells were expanded for 48 hours before selection with 1 622 
µg/ml puromycin. At 72 hours post-puromycin selection, half of the volume of each 623 
quadruplicate was pelleted and frozen down to constitute the day 0 time point, and cells 624 
were maintained in culture and split every two days to keep at least 6×106 cells per 625 
replicate until day 36. Genomic DNA was isolated by proteinase K digestion and 626 
isopropanol precipitation from each pellet at day 0 and day 36 time-points. The 627 
antisense strand of shRNA was amplified from genomic DNA using primers that include 628 
1-basepair mutations to barcode individual samples. Hairpins were amplified in multiple 629 
50 µl reactions using HotStar Taq (Qiagen). After PCR amplification, samples were 630 
pooled and prepared for sequencing with Illumina’s genomic adaptor kit. At least 41 631 
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bases of the PCR product were sequenced with an Illumina HiSeq 2000 machine. 632 
shRNAs with less than 100 reads in the input sample were excluded from further 633 
analysis, and read numbers for each shRNA were normalized to the total read numbers 634 
per sample to allow for cross-comparison between samples. We then compared using 635 
an EdgeR/RIGER method the hairpin representation between day 0 and day 36 and 636 
thus identified genes whose depletion blocked or enhanced cell proliferation. EdgeR 637 
(R/Bioconductor v.3.3 package38) provided the statistical analysis of count data from the 638 
day 0 versus day 36 time-points per cell lines. Next, the RNAi gene enrichment ranking 639 
(RIGER) score was given by examination of the position of each hairpin targeting each 640 
gene in the full ranked list of the 361 shRNAs. The enrichment scores and the gene 641 
ranking were finally computed based on the RIGER v.0.1 module39 available from the 642 
GENE-E platform (http://www.broadinstitute.org/cancer/software/GENE-E/). The GENE-643 
E platform is now replaced by the Morpheus platform which is available at the same 644 
URL as GENE-E. 645 
 646 
Metabolite Profiling for Steady-state and Targeted Flux Analyses  647 
To determine the relative levels of intracellular metabolites, extracts were 648 
prepared and analyzed by LC/MS/MS. Twenty-four hours after sorting and 16 hours 649 
prior to metabolite extraction, 7.5x106 cells were plated in triplicate in an incubation 650 
media: DMEM media with no glucose, no glutamine, and no sodium pyruvate (Gibco) 651 
supplemented with 1 g/L D-glucose (Sigma), 1.5 mM L-glutamine (Sigma), 5 mM 652 
sodium pyruvate (ThermoFisher Scientific), 4 g/L BSA (Sigma), 1 µg/ml insulin (#91077, 653 
Sigma), 30 µg/mL transferrin (#T0665, Sigma), 20 ng/ml IL-3 (#213-13, Peprotech), 20 654 
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ng/ml IL-6 (#216-16, Peprotech), 100 ng/ml FLT3-Ligand (#250-31L, Peprotech), and 655 
100 ng/ml SCF (#250-03, Peprotech). For L-Arginine 13C6 flux studies, cells were 656 
washed twice with PBS and then incubated in DMEM no glutamine, no lysine, and no 657 
arginine media supplemented with 466 µM L-Arginine 13C6, 1 mM Lysine, 1.5 mM L-658 
glutamine, 5 mM sodium pyruvate, and 10% dialyzed FBS. Metabolites were extracted 659 
on dry ice with 4 mL of 80% methanol (-80°C), as described previously40. Insoluble 660 
material was pelleted by centrifugation at 3000g for 5 min, followed by two subsequent 661 
extractions of the insoluble pellet with 0.5 ml of 80% methanol, with centrifugation at 662 
16000g for 5 min. The 5 ml metabolite extract from the pooled supernatants was dried 663 
down under nitrogen gas using an N-EVAP (Organomation Associates, Inc).  664 
 665 
Dried pellets were re-suspended using 20 μL HPLC grade water for mass 666 
spectrometry. 10 μl were injected and analyzed using a 5500 QTRAP triple quadrupole 667 
mass spectrometer (AB/SCIEX, BIDMC Mass Spec Core, Boston, MA, USA) coupled to 668 
a Prominence UFLC HPLC system (Shimadzu) via selected reaction monitoring (SRM) 669 
of a total of 292 endogenous water soluble metabolites for steady-state analyses of 670 
samples. Some metabolites were targeted in both positive and negative ion mode for a 671 
total of 391 SRM transitions using pos/neg polarity switching. ESI voltage was +4900V 672 
in positive ion mode and –4500V in negative ion mode. The dwell time was 3 ms per 673 
SRM transition and the total cycle time was 1.55 seconds. Approximately 10-14 data 674 
points were acquired per detected metabolite. Samples were delivered to the MS via 675 
normal phase chromatography using a 4.6 mm i.d x 10 cm Amide Xbridge HILIC column 676 
(Waters Corp.) at 350 μL/min. Gradients were run starting from 85% buffer B (HPLC 677 
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grade acetonitrile) to 42% B from 0-5 minutes; 42% B to 0% B from 5-16 minutes; 0% B 678 
was held from 16-24 minutes; 0% B to 85% B from 24-25 minutes; 85% B was held for 679 
7 minutes to re-equilibrate the column. Buffer A was comprised of 20 mM ammonium 680 
hydroxide/20 mM ammonium acetate (pH=9.0) in 95:5 water:acetonitrile. Peak areas 681 
from the total ion current for each metabolite SRM transition were integrated using 682 
MultiQuant v2.0 software (AB/SCIEX). For stable isotope labeling experiments, custom 683 
SRMs were created for expected 13C incorporation in various forms for targeted 684 
LC/MS/MS. Peak areas of metabolites detected by mass spectrometry were normalized 685 
to median and then normalized to protein concentrations. A Student’s t-test was 686 
performed to assess significance of all pairwise comparisons. All data are log2-687 
transformed and normalized against the average control condition. No or small 688 
variations in metabolite production compared to average control condition appears 689 
closest to the white color on the heatmap. Decreased or increased metabolite 690 
production compared to the average control condition is represented by a gradient of 691 
color from blue to red respectively. The MetaboAnalyst software 692 
(www.metaboanalyst.ca) was used to perform pathway enrichment analysis on the set 693 
of top metabolites hits identified by steady-state profiling. No specific manual settings 694 
were needed to analyze the list of metabolites. 695 
 696 
ChIP-sequencing and ChIP-qPCR 697 
A Runx1 gene track generated by ChIP-sequencing for the analysis of murine 698 
Evi1 binding peaks was obtained from Dr. Archibald S. Perkins (University of Rochester 699 
Medical Center, New-York, NY, USA). The human RUNX1 gene track was obtained 700 
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from publically available ChIP-sequencing data generated by Bard-Chapeau et al.19. 701 
The conservation score between species was computed based on phasCons data for 702 
hg18 and mm941. Gene tracks and EVI1-binding peaks were aligned using IGV 703 
software42. 704 
ChIP-qPCR was performed as described by Bernt et al.43. Briefly, crosslinking 705 
was performed in cell culture medium containing 1% formaldehyde with gentle rotation 706 
for 5 minutes at room temperature. Fixation was stopped by the addition of glycine (125 707 
mM final concentration). Fixed cells were washed twice in ice-cold PBS and then 708 
resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 709 
supplemented with Complete-mini-protease inhibitor cocktail (Roche)). Chromatin was 710 
sheared to approximately 200bp fragments by Covaris ultra-sonication and 711 
immunoprecipitated. Precipitates were washed sequentially with ice cold low salt wash 712 
(0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), 713 
high salt wash (0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 714 
mM NaCl), LiCl wash (0.25 M LiCl, 1% IGEPAL CA-630, 1% deoxycholic acid, 1 mM 715 
EDTA, 10 mM Tris-HCl, pH 8.1) and TE wash (1 mM EDTA, 10 mM Tris-HCl, pH 8.1) 716 
and eluted in elution buffer (1% SDS, 0.1M NaHCO3). Eluted DNA fragments were 717 
analyzed by qPCR. Primers used for ChIP-qPCR are listed below. 718 
 719 
 720 
Western Immunoblotting 721 
Targets Species Forward Reverse
Runx1 Mus Musculus CTCCCTCCCTCTCTCCTCTATTAAA GAGTTCTTGTCTTTCTGCGTCATG
Ckmt1 Mus Musculus GTCTGAGTATGCACTTCGCAAAA GGTCATCAGGGAGTCTCTGTCTTC
CKMT1 Homo Sapiens AGACCTGTGCCTGCCTGTTC GGAGGAGAAGGTAAAGTGAGGTGAA
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Western immunoblotting was performed as described previously44 using cell 722 
lysates normalized for total protein content. Lysates were boiled in Laemmli sample 723 
buffer and run on SDS–polyacrylamide gel electrophoresis (PAGE) prior to transfer to 724 
nitrocellulose membranes, and immunoblotting. A list of antibodies used for western 725 
immunoblotting is listed below. 726 
 727 
Flow Cytometry 728 
Cell lines were washed in PBS-0.1% BSA-2 mM EDTA before a 45 minute 729 
incubation with an anti-human CD117 antibody. Cells were then washed twice with PBS 730 
containing 0.1% BSA and 2 mM EDTA before analysis with BC FACScanto II (BD 731 
Biosciences). 732 
 733 
Primary patient AML cells were washed in PBS containing 0.1% BSA and 2 mM 734 
EDTA before a 45-minute incubation with a combination of anti-human PE-Cy7 CD13 735 
and CD33 (used at 1/50) or PE-Cy7 isotype control antibodies. Cells were then washed 736 
twice with PBS-0.1% BSA-2 mM EDTA before a 20-minute fixation with BD 737 
Cytofix/CytoPerm Fixation and Permeabilization Solution (BD Biosciences). Cells were 738 
then washed three times with BD Perm/Wash Buffer and incubated for 45 minutes at 739 
4°C with a non-conjugated anti-human EVI1 antibody (used at 1/50), or the 740 
corresponding isotype control antibody. Cells were washed three times with Perm/Wash 741 
Buffer and were incubated for 35 minutes with an Alexa Fluor 488 goat anti-rabbit IgG 742 
antibody used at 1/500 (Invitrogen). Cells were washed three times in Perm/Wash 743 
Buffer and analyzed using a BD FACSCanto II analyzer. To account for any background 744 
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fluorescence, the EVI1 mean fluorescence level was normalized to the mean 745 
fluorescence level of its corresponding isotype control. This normalized value was then 746 
scaled for each patient using the Z-Score calculation across all patient samples. 747 
 748 
Murine bone marrow and spleen were collected from each organ, washed with 749 
PBS containing 0.1% BSA and 2 mM EDTA and lysed for 10 minutes with red blood cell 750 
lysis buffer (Sigma). After two washing steps with PBS containing 0.1% BSA and 2 mM 751 
EDTA, bone marrow cells were stained for 30 minutes at 4°C with a combination of anti-752 
lineage cocktail, Sca-1, c-KIT, CD16/32 and CD34 antibodies and spleen cells were 753 
incubated for 5 minutes at 4°C with mouse BD Fc Block™ (BD Biosciences) before 754 
staining with the combination of Mac-1/Gr-1 antibodies. Stained cell subpopulations 755 
were analyzed with BD LSR-II analyzer (BD Biosciences).  756 
A list of antibodies used for western immunoblotting and flow cytometry is listed 757 
below. 758 
 759 
Targets Conjugate References Manufacturer 
ACTIN Non MS-1295-P Neomarkers 
CD5 APC 17-0051 eBioscience 
CD13 PE-Cy7 25-0138-42 eBioscience 
CD16/32 PerCP-Cy5.5 45-0161-82 eBioscience 
CD33 PE-Cy7 25-0338-42 eBioscience 
CD34 eFluor 450 48-0341-82 eBioscience 
CD45.1 PE-Cy7 25-0453-82 eBioscience 
CD45.2 APC 17-0454-82 eBioscience 
CD45R APC 17-0452 eBioscience 
CD117 PE-Cy7 313212 BioLegend 
CD127 APC 17-1271 eBioscience 
c-KIT PE-Cy5 105810 BioLegend 
CKMT1 Non H00001159M16 Abnova 
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CKMT1 Non H00001159-D01 Abnova 
CS Non 14309S Cell Signaling Technology 
EVI1 Non 2593 Cell Signaling Technology 
Evi1 Non Custom Dr. Archibald Perkins 
GR-1 APC 17-5931-81 eBioscience 
GAPDH Non sc-25778 Santa-Cruz Biotechnology 
H3K4Me3 Non Ab8580 Abcam 
H3K27Ac Non Ab4729 Abcam 
H3K27Me3 Non Ab6002 Abcam 
HSP60 Non sc-1722 Santa-Cruz Biotechnology 
HSP90 Non sc-13119 Santa-Cruz Biotechnology 
Lineage APC BDB558074 BD Biosciences 
Mac-1 PE-Cy7 101216 BioLegend 
RUNX1 Non Ab23980 Abcam 
RUNX1 Non 8529 Cell Signaling Technology 
Sca-1 PE-Cy7 25-5981-82 eBioscience 
SDHA Non 11998P Cell Signaling Technology 
VINCULIN Non Ab18058 Abcam 
 760 
Genome-wide Expression Analysis 761 
 762 
Genome Profiling of Evi1-overexpressing Murine Progenitor Cells.  763 
eGFP-positive control and Evi1-overexpressing progenitor cells were sorted and 764 
total RNA was extracted and profiled using the GeneChip Mouse Gene 1.0 ST Array 765 
from Affymetrix (GSE3910316). 766 
Comparative Marker and GSEA Analyses. The 6 samples in the GSE39103 767 
data available from the Gene Expression Omnibus (GEO) repository 768 
(http://www.ncbi.nlm.nih.gov/geo/) were separated into 2 groups: control versus Evi1-769 
overexpressing samples. The Comparative Marker Selection module from GenePattern 770 
v3.9.345 was used to identify individual genes differentially expressed between the two 771 
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groups. A permutation p value ≤ 0.05, a Benjamini–Hochberg false discovery rate (FDR) 772 
≤ 0.05 accounting for multiple hypothesis testing, and an absolute fold change ≥ 2 773 
served as cutoff for significant genes. The Gene Set Enrichment Analysis (GSEA) 774 
v.2.1.0 software46,47 was used to identify pathways, or groups of functionally related 775 
genes, deregulated by Evi1 overexpression. The goal of GSEA is to identify groups of 776 
genes sharing common biologic function (gene sets), which are distributed at the top or 777 
at the bottom of the ranked list of differentially expressed genes. The significance of the 778 
enrichment score is estimated on the basis of a permutation p value and adjusted for 779 
multiple hypotheses testing through FDR. The set of differentially expressed genes 780 
accounting for the enrichment signal is called the leading edge. GSEA was run on the 781 
c2 collection of 4725 curated gene sets from MSigDB v.5.0 782 
(http://software.broadinstitute.org/gsea/msigdb/). Gene sets with less than 15 genes or 783 
more than 500 genes were excluded from the analysis. Gene sets with a nominal p 784 
value ≤ 0.05 and FDR ≤ 0.25 were considered significant. The gene ranking metric in 785 
the weighted enrichment score was the 2-sided SNR, and the p values were calculated 786 
using 1,000 permutations of the phenotype. 787 
Metabolic Network. Each metabolic gene deregulated upon Evi1 788 
overexpression was assigned to a functional group based on the c2 collection from 789 
MSigDB (http://www.genomespace.org). The enrichment results were visualized with 790 
the Enrichment Map module,48,49 which organizes the significant gene sets into a 791 
network called an “enrichment map.” In the enrichment map, the nodes correspond to 792 
gene sets and the edges reflect significant overlap between the nodes according to a 793 
two-tailed Fisher exact test. The hubs correspond to collections of gene sets with a 794 
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unifying class label according to gene ontology (GO) biologic processes. The size of the 795 
nodes is correlated with the number of genes in the gene set. 796 
 797 
Gene Expression Profiling of Cyclocreatine Treatment.  798 
TF-1, UT-7 and UCSD-AML1 cells were treated in quadruplicate with either 799 
vehicle or 3 mM cyclocreatine for 24 hours. Total RNA was extracted and profiled by 800 
RNA sequencing (HiSeq, Illumina) at the BioMicroCenter, Massachusetts Institute of 801 
Technology (Cambridge, MA, USA). The total number of reads for individual samples 802 
ranged from 44 to 48 Mb. Quality control tests for the unmapped reads were performed 803 
using the FASTQC software 804 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were aligned to 805 
the GRCh37 (hg19) GENCODE v17 annotated human reference genome by using 806 
TopHat250. FPKM scores for genes were computed based on the RSEM R software 807 
package51. Expression data was evaluated as log2 (FPKM). The significance of the 808 
differential expression between the control and cyclocreatine treatment phenotypes was 809 
estimated using the EBSeq method implemented in R (Bioconductor v.3.352), based on 810 
the significance cutoff 0.05 for the posterior probability. The aligned RNASeq data is 811 
available at the GEO repository(GSE86151). 812 
 813 
Comparative Marker Analysis. The 24 samples available in the RNAseq data 814 
were separated into two groups: 12 =vehicle-treated and 12 =cyclocreatine treated. The 815 
Comparative Marker Selection module from GenePattern v.3.9.345 was employed to 816 
identify individual genes that were differentially expressed between the two conditions. 817 
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The analysis was performed by applying a 2-sided Signal-to-Noise Ratio (SNR) test 818 
followed by 1000 permutations of phenotype labels. The settings for the SNR 819 
parameters were log-transformed-data:no, complete:no, balanced:no, smooth p values: 820 
yes. 821 
A “core” cyclocreatine signature consisting of 54 genes upregulated and of 53 822 
genes downregulated between the vehicle and cyclocreatine-treated samples was 823 
defined based on the cut-offs SNR permutation p value ≤ 0.05, Benjamini-Hochberg 824 
false discovery rate (FDR) ≤ 0.05, and absolute fold change for log2 (FPKM) scores ≥ 825 
1.5. In addition, a “relaxed” cyclocreatine signature consisting of 366 upregulated and 826 
474 downregulated genes between the two conditions was defined based on the cut-827 
offs SNR permutation p value ≤ 0.05, Benjamini-Hochberg false discovery rate (FDR) ≤ 828 
0.05 and absolute fold change for log2 (FPKM) scores ≥ 0.5. The “core” cyclocreatine 829 
signature is presented in Supplementary Tables S3 and S4. 830 
 831 
GSEA analysis and Scatter Plot. The Gene Set Enrichment Analysis (GSEA 832 
v2.1.0) software46,47 was used to identify functional associations of the molecular 833 
phenotypes induced by cyclocreatine with a compendia of gene signatures including the 834 
MSigDB v5.047,53 collections c2 of 4,725 curated gene sets and c6 of 189 oncogenic 835 
signatures, the DMAP collection of hematopoietic lineage differentiation signatures53, 836 
and with four AML differentiation gene signatures available from Gene Expression 837 
Omnibus (GEO) database: Vitamin D- and PMA-induced differentiation signatures 838 
(accession no. GSE995 54); JQ1-induced differentiation signature (accession no. 839 
GSE2979955), and DOT1L inhibitor-induced differentiation signature (accession no. 840 
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GSE2982856). Gene sets with less than 15 genes or more than 500 genes were 841 
excluded from the analysis. Gene sets with an FDR ≤ 0.25 and a nominal p value ≤ 0.05 842 
were considered significant hits. The results were plotted on volcano plots and 843 
visualized on a functional network called an “enrichment map”. In the enrichment map, 844 
the nodes correspond to gene sets and the edges reflect significant overlap between 845 
the nodes according to a two-tailed Fisher exact test. The size of the nodes is correlated 846 
with the gene set enrichment significance (-log10 (p value)). The hubs correspond to 847 
collections of gene sets with a unifying functional category label. 848 
 849 
In Silico Tests for CKMT1 High Versus CKMT1 Low Expression in Primary AML 850 
Samples 851 
The in silico test used to determine the proportion of EVI1high/RUNX1low, 852 
EVI1high/RUNX1high, EVI1low/RUNX1low, and EVI1low/RUNX1high patients exhibiting high 853 
CKMT1 versus low CKMT1 expression levels was carried out on the Affymetrix U133 854 
Plus2 gene expression data GSE14468857 (526 AML samples) and GSE1035858 (279 855 
AML samples). Data were downloaded from the InSilico DB Genomic Datasets Hub 856 
(http://www.genomespace.org). EVI1, RUNX1, and CKMT1 expression levels were 857 
computed for each sample of these two cohorts and were further transformed into a z-858 
score by subtracting the average of the EVI1, RUNX1, and CKMT1 expression levels 859 
assigned to all other samples and by dividing the result to their standard deviation. For 860 
each patient, high versus low EVI1, RUNX1, and CKMT1 expression levels were 861 
evaluated based on the absolute cut-off of a z-score ≥ 0.58 is high expression and a z-862 
score ≤ -0.58 is low expression. The significance of the differences between the 863 
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proportions of patients with CKMT1 high versus low expression within patient subgroups 864 
with high and low EVI1 and RUNX1 expressions was estimated by applying the two-865 
tailed Fisher’s Exact Test implemented in the function fisher.test (library stats, R 3.2, 866 
http://cran.r-project.org/). 867 
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LEGENDS TO FIGURES 927 
 928 
Figure 1. EVI1 overexpression imparts new metabolic dependencies on AML 929 
cells. 930 
(A) Quantitative comparison by GSEA of the c2 collection of curated gene sets available 931 
from MSigDB v.5.0 for murine LinLow Evi1-overexpressing versus control bone marrow 932 
samples (GSE 34729). Data are presented as a volcano plot of -log10 (FDR) versus the 933 
normalized enrichment score for each evaluated gene set. Triangles indicate sets 934 
related to proliferation (green), cell differentiation (blue), and metabolism (red), and gray 935 
dots indicate all other c2 gene sets. 936 
(B) Metabolic network showing gene sets altered in the Evi1 overexpression signature 937 
generated from GSE 34729. Black, dark grey, light grey, and white colors indicate an 938 
enrichment odds ratio (OR) above 3, between 2 and 3, between 1 and 2, and below 1, 939 
respectively. 940 
(C) Pathway analysis integrating enrichment and pathway topology analyses 941 
(MetaboAnalyst) of the steady-state metabolite profile from control versus Evi1-942 
overexpressing LinLow murine bone marrow cells. Top 15 out of a total of 45 metabolic 943 
pathways are represented based on a FDR ≤ 0.1 and p value ≤ 0.05. “Hits” represents 944 
the number of metabolites that scored in the steady-state profile and “Total” represents 945 
the number of metabolites present in the given metabolic pathway. Metabolic pathways 946 
with a - log10 (FDR) ≥ 1.5 are depicted in red, 1 ≤ - log10 (FDR) < 1.5 are in orange, and 947 
- log10 (FDR) < 1 in beige. 948 
(D) Scatterplot of hits significantly depleted (in blue) or enriched (in red) from an shRNA 949 
library targeting 67 metabolism-related genes in the human TF-1 (top) and UCSD-AML1 950 
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(bottom) cell lines. Hits which did not score are depicted in black. Data are presented as 951 
volcano plots of -log10 (FDR) versus the RIGER enrichment score for each gene. 952 
(E) Heatmap of the metabolism genes differentially expressed by genomic profiling in 953 
GSE 34729 upon Evi1 overexpression in LinLow bone marrow cells (left panel), and 954 
heatmap of genes either depleted (in blue) or enriched (in red) in the shRNA screen in 955 
TF-1 and UCSD-AML1 cells (right panel). Shown in blue text are genes both 956 
upregulated upon Evi1 overexpression and depleted in the shRNA screen. CT, control. 957 
Each column for each condition represents a technical replicate (n=3 per condition).  958 
(F) Growth of TF-1 cells infected with hairpins directed against either CKMT1, SDHA, or 959 
CS (left panel). Immunoblot confirming shRNA target knockdown (right panel). shCT, 960 
control shRNA. Error bars represent mean ± SD. * and # p value ≤ 0.05 was calculated 961 
on the latest time point using a nonparametric Kruskall-Wallis test and Dunn’s multiple 962 
comparisons test. Data are representative of two independent experiments. 963 
 964 
Figure 2. EVI1-positive cells highly express and are dependent on CKMT1.  965 
(A) Immunoblot for EVI1, CKMT1, and HSP60 (loading control) from a panel of human 966 
AML cell lines with high or low EVI1 expression. 967 
(B-C) Creatine kinase activity (B) and distribution of IC50 (C) for human EVI1 high 968 
versus low cell lines treated with cyclocreatine (Ccr). p value calculated using 969 
nonparametric Mann-Whitney test. Error bars represent mean ± SD of 8 low EVI1-970 
expressing and four high EVI1-expressing human cell lines. 971 
(D) Eleven human AML cell lines were infected with two CKMT1-directed miR30-972 
shRNAs. Growth after treatment with 0.5 μg/ml doxycycline is normalized to the control 973 
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shRNA and shown relative to day 0 (time of seeding), with error bars representing the 974 
mean ± SD of seven technical replicates. Each experiment in A-D was performed at 975 
least two independent times. 976 
(E) Z Score normalization of EVI1 expression across a panel of CD13/33-gated bone 977 
marrow cells from 68 patient AML samples. Red bars indicate the four patients with the 978 
highest EVI1 expression level. 979 
(F) Immunoblot for EVI1, CKMT1, and GAPDH (loading control) from bone marrow 980 
samples sub-selected from panel (E). 981 
(G) Distribution of IC50 for EVI1 high versus low patient samples in response to 982 
treatment with cyclocreatine (Ccr). Red squares represent the four patient samples from 983 
panel (F) highlighted in red. p value calculated using nonparametric Mann-Whitney test. 984 
Error bars represent mean ± SD of 10 low EVI1-expressing and four high EVI1-985 
expressing human primary samples. 986 
 987 
Figure 3. EVI1-mediated RUNX1 downregulation promotes CKMT1 expression. 988 
(A-B) Immunoblot for Evi1, Ckmt1 and Gapdh (A) and qRT-PCR for Ckmt1 expression 989 
(B) from LinLow, c-Kit+ murine bone marrow cells infected with an empty or Evi1-990 
encoding construct. Error bars represent the mean ± SD of four technical replicates. * p 991 
value ≤ 0.05 in comparison with empty control vector calculated using a Mann-Whitney 992 
test. 993 
(C) qRT-PCR for CKMT1 expression level in human TF-1 and UCSD-AML1 cells 994 
infected with shControl (shCT) or three EVI1-targeting shRNAs. Error bars represent 995 
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mean ± SD of four technical replicates. * and # p value ≤ 0.05 in comparison with shCT 996 
calculated using a Mann-Whitney test. 997 
(D) Luciferase reporter assay from human 293E cells co-expressing a vector encoding 998 
EVI1, and wild-type or several truncated forms of the human CKMT1 promoter flanking 999 
a luciferase cassette. 1000 
(E) Luciferase reporter assay from human 293E cells co-expressing a vector encoding 1001 
EVI1 and a luciferase-flanked human CKMT1 promoter either wild-type or deleted for 1002 
the RUNX1-binding site. 1003 
(F) Luciferase reporter assay from human 293E cells co-expressing vectors encoding 1004 
EVI1 and RUNX1. 1005 
(G) Immunoblot for EVI1, RUNX1, CKMT1, and HSP60 (loading control) from human 1006 
TF-1 cells infected with the indicated combinations of EVI1- and RUNX1-directed 1007 
shRNAs. 1008 
(H) Representation of EVI1 binding peaks on RUNX1 gene tracks available from two 1009 
ChIP-sequencing experiments performed by Bard-Chapeau et al.19 and Glass et al.20. 1010 
(I-L) LinLow, c-Kit+ murine bone marrow cells overexpressing a vector encoding Evi1 (I-1011 
J), or human UCSD-AML1 cells infected with shControl (shCT) and three EVI1-directed 1012 
shRNAs (K), or human UCSD-AML1 cells infected with combinations of EVI1- and 1013 
RUNX1-directed shRNAs (L) following ChIP with the indicated ChIP antibodies (ChIP 1014 
Ab) and qPCR on the indicated promoter regions. Results are represented as fold 1015 
enrichment over input. 1016 
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(D-L) Error bars represent mean ± SD of three technical replicates.* p value ≤ 0.05 1017 
calculated using a Welch’s t-test. Each experiment in A-L was performed at least two 1018 
independent times. 1019 
(M) TF-1-Luc cells engineered to overexpress CSF2 for efficient engraftment were 1020 
infected with a combination of two EVI1- and one RUNX1-directed shRNAs before tail 1021 
vein injection. Bioluminescence was quantified weekly as a measure of disease burden. 1022 
Data are represented as mean ± SEM of 5 mice per cohort. * p value ≤ 0.05 was 1023 
calculated on the latest time point using nonparametric Mann-Whitney test. 1024 
(N) Bar graph showing the number of primary patient AML samples with either 1025 
EVI1high/RUNX1low, EVI1high/RUNX1high, EVI1low/RUNX1low, or EVI1low/RUNX1high 1026 
expression and displaying CKMT1 high versus low expression level (absolute cut-off of 1027 
a z-score ≥ 0.58 is high expression and a z-score ≤ - 0.58 is low expression) in two 1028 
cohorts: GSE14468 and GSE10358. p value calculated using a Fisher exact test. 1029 
 1030 
Figure 4. Blockade of the arginine-creatine pathway upon CKMT1 inhibition 1031 
impairs both mitochondrial respiration and ATP production in EVI1-positive AML 1032 
cells. 1033 
(A) Schematic of arginine metabolism and enzymes involved in this process. 1034 
(B-C) Heatmaps of metabolite products of arginine metabolism that are differentially 1035 
regulated in human UCSD-AML1 cells infected with either control (shCT) or CKMT1-1036 
directed shRNAs (B) or in human TF-1 cells treated with 3 mM cyclocreatine (Ccr) for 1037 
12 hours in combination with 1 mM phospho-creatine (P-Cr) (C) before a 30-min pulse 1038 
labeling with L-Arginine 13C6. Metabolites scoring with a p value ≤ 0.05 are shown as 1039 
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log2 fold change normalized to the average control condition. Each column for each 1040 
condition represents a technical replicate (n=3 per condition). 1041 
(D-E) Growth inhibition of human TF-1 and UCSD-AML1 cells treated with increasing 1042 
concentrations of cyclocreatine (Ccr) (D) or infected with control (shCT) or CKMT1-1043 
directed shRNAs (E) in combination with 1 mM phospho-creatine (P-Cr). Error bars 1044 
represent mean ± SD of five technical replicates.* p value ≤ 0.05 in comparison with 1045 
shControl calculated using a Mann-Whitney test. 1046 
(F) Colony-forming assay for 5 rounds of serial replating from control or Evi1-1047 
overexpressing murine LinLow, c-Kit+ bone marrow cells treated with 3 mM cyclocreatine 1048 
(Ccr) in combination with 1 mM phospho-creatine (P-Cr). # p value ≤ 0.05 calculated 1049 
using Welch’s t-test in comparison with the control condition. Error bars represent mean 1050 
± SEM of three technical replicates. 1051 
(G) Heatmap of the top upregulated or downregulated metabolites (p value ≤ 0.05 and 1052 
absolute log2 fold change ≥ 1.5 in at least one of the two CKMT1-directed shRNAs 1053 
condition versus average shControl condition) identified by steady-state metabolism 1054 
profiling in human TF-1 and UCSD-AML1 cells infected with either control (shCT) or two 1055 
CKMT1-directed shRNAs. Each column for each condition represents a technical 1056 
replicate (n=3 per condition in two individual human EVI1-positive cell lines). 1057 
(H) Pathway analysis integrating enrichment and pathway topology analyses 1058 
(MetaboAnalyst) of the list of top metabolites from panel (G). Top enriched metabolic 1059 
pathways are represented based on a FDR ≤ 0.25 and p value ≤ 0.05. “Hits” represents 1060 
the number of metabolites that scored in the steady-state profile and “Total” represents 1061 
the number of metabolites present in the given metabolic pathway. Metabolic pathways 1062 
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with a - log10 (FDR) ≥ 1.5 are depicted in red, 1 ≤ - log10 (FDR) < 1.5 are in orange, and 1063 
- log10 (FDR) < 1 in beige. 1064 
(I) ADP / ATP ratio in a panel of 12 human AML cell lines treated with 5 mM 1065 
cyclocreatine (Ccr) for 12 hours. * p value ≤ 0.05 in comparison with the control 1066 
condition calculated using a Mann-Whitney test. Error bars represent mean ± SD of four 1067 
technical replicates. 1068 
(J) Intracellular ATP level in the indicated human EVI1-positive AML cell lines treated 1069 
with 5 mM cyclocreatine (Ccr) in combination with 1 mM phospho-creatine (P-Cr) for 12 1070 
hours. * and # p value ≤ 0.05 calculated using a Mann-Whitney test in comparison with 1071 
the control condition and Ccr-treated condition respectively. Error bars represent mean 1072 
± SD of four technical replicates. 1073 
(K) Mitochondrial Oxygen Consumption Rate (OCR) of human UCSD-AML1 and TF-1 1074 
cells treated with 5 mM cyclocreatine (Ccr) in combination with 1 mM phospho-creatine 1075 
(P-Cr) for 12 hours prior to measurement under basal conditions, following sequential 1076 
injections of 1 μM ATP synthase inhibitor oligomycin, 1 μM of the uncoupling agent 1077 
FCCP, and 1 μM of the complex I and III inhibitors rotenone and antimycin A, 1078 
respectively. * p value ≤ 0.05 calculated using a Mann-Whitney test in comparison with 1079 
the control condition. Error bars represent mean ± SD of 4 technical replicates.  1080 
Each experiment was performed at least two independent times except in G and H in 1081 
which two different EVI1-positive human cell lines transduced with two different CKMT1-1082 
directed shRNAs were profiled using metabolomics. 1083 
 1084 
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Figure 5. Inhibition of the creatine kinase pathway alters the viability of EVI-1-1085 
positive AML cells via cell cycle blockade and apoptosis induction. 1086 
(A) Heatmap of the top common up- and down-regulated genes in human TF-1, UT-7, 1087 
and UCSD-AML1 cell lines treated with cyclocreatine for 24 hours. p value ≤ 0.05, FDR 1088 
≤ 0.05, and absolute fold change for log2 (FPKM) scores ≥ 1.5. Each column for each 1089 
condition represents an independent biological replicate (n=3 per condition in three 1090 
individual human EVI1-positive cell lines). 1091 
(B-C) A cyclocreatine signature identified by RNAseq was interrogated by GSEA across 1092 
the MsigDB and DMAP database for vehicle versus cyclocreatine-treated AML cells. (B) 1093 
Top enriched upregulated (in red) and downregulated (in blue) gene sets upon 1094 
cyclocreatine treatment are depicted in a functional network. (C) Quantitative 1095 
comparison of these gene sets of interest (in blue or red) versus all other available gene 1096 
sets (in gray). Data are presented as a volcano plot of -log10 (p value) versus 1097 
Normalized Enrichment Score (NES) for each evaluated gene set.  1098 
(D-E) May-Grünwald-Giemsa staining of indicated human AML cell lines treated with 8 1099 
mM cyclocreatine for 9 days (D), or infected with a control (shCT) or a CKMT1-directed 1100 
shRNA (E). 1101 
(F) Cell size measurement of indicated human AML cell lines treated with 8 mM 1102 
cyclocreatine for 9 days (top panel) or infected with CKMT1-directed shRNAs (bottom 1103 
panel). * p value ≤ 0.05 calculated using Welch’s t-test in comparison with the control 1104 
condition. Error bars represent mean ± SD of three technical replicates. 1105 
(G) Cell cycle analysis at the indicated time points of human EVI1-positive cell lines 1106 
treated with cyclocreatine. 1107 
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(H) FACS plots showing Annexin V (AV) / propidium iodide (PI) profile of the indicated 1108 
human AML cell lines treated with 8 mM cyclocreatine (Ccr) for 5 days. 1109 
(I) FACS analysis of the expression of CD117 cell surface marker in the indicated 1110 
human AML cell lines treated with 8 mM cyclocreatine for 9 days (bottom panel) or 1111 
infected with CKMT1-directed shRNAs (top panel). A representative FACS plot from 1112 
each cell line is shown. 1113 
(J) Colony formation assay for 2 to 3 rounds of serial replating from indicated human 1114 
AML cell lines treated with either 3 mM or 10 mM cyclocreatine (Ccr). Results represent 1115 
the average of triplicate assays. * p value ≤ 0.05 calculated using a Welch’s t-test in 1116 
comparison to the control condition. Error bars represent mean ± SEM.  1117 
Each experiment in D-J was performed at least two independent times. 1118 
 1119 
Figure 6. CKMT1 knockdown preferentially impairs development of EVI1-positive 1120 
human and murine myeloid leukemias, without affecting normal progenitor cell 1121 
viability. 1122 
(A) Western immunoblot for Evi1/EVI1, Ckmt1/CKMT1, and Gapdh/GAPDH (loading 1123 
control) in murine bone marrow cells from wild-type (WT), N-RasG12D, or N-RasG12D + 1124 
Evi1 mouse. Human UCSD-AML1 cell line is used as positive control for EVI1 and 1125 
CKMT1 expression. 1126 
(B) Immunoblot indicating the level of Ckmt1 knockdown in murine RFP-sorted bone 1127 
marrow cells seven days post-doxycycline induction. 1128 
(C) Kaplan-Meier curves showing overall survival of mice (n = 5 for each group except 1129 
for N-RasG12D + Evi1 shCT + dox group, for which n = 6) transplanted with cells 1130 
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expressing each combination of indicated constructs. Statistical significance determined 1131 
by log-rank (Mantel-Cox) test. * p value ≤ 0.05 by comparison with shControl (shCT) 1132 
within the N-RasG12D or the N-RasG12D + Evi1 group. 1133 
(D) Spleen weight and white blood cell (WBC) count of four mice per group when 1134 
shControl mice became moribund. P value calculated using a Mann-Whitney test. Error 1135 
bars represent mean ± SEM. 1136 
(E) Proportion of Mac-1+ / Gr-1+ cells in spleens from four mice per group. p value 1137 
calculated using a Mann-Whitney test. Error bars represent mean ± SEM. 1138 
(F) Proportion of CMP (CD16/32-/CD34+), GMP (CD16/32+/CD34+), and MEP (CD16/32-1139 
/CD34-) cell populations on gated LinLow/Sca-1-/c-Kit+ myeloid progenitors when 1140 
shControl became moribund. RFP and Venus expression were evaluated on every 1141 
leukemic cell population. One representative moribund mouse from each group is 1142 
shown. 1143 
(G-H) Low U937-Luc (G) and high TF-1 CSF2+-Luc (H) EVI1-expressing human cell 1144 
lines were either infected with two doxycycline-inducible CKMT1-directed miR30-1145 
shRNAs (top panel) before tail vein injection, or treated with 1g/kg/day cyclocreatine 1146 
(Ccr) 10 days post-injection (bottom panel). TF-1-Luc cells were engineered to 1147 
overexpress CSF2 for efficient engraftment in mice. Bioluminescence was quantified 1148 
weekly as a measure of disease burden. Arrows indicates beginning of doxycycline 1149 
(Dox) or cyclocreatine (Ccr) treatments. Data are represented as mean ± SEM of 5 mice 1150 
per cohort. p value was calculated on the latest time point using nonparametric Mann-1151 
Whitney test. Kaplan-Meier curves showing overall survival of each group of mice is 1152 
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shown in the right panel. Statistical significance determined by log-rank (Mantel-Cox) 1153 
test. n.s, not significant. 1154 
(I) Low U937-Luc (top panel) and high TF-1 CSF2+-Luc (bottom panel) EVI1-expressing 1155 
human cell lines were treated with 1g/kg/day cyclocreatine (Ccr) in combination with 1156 
phospho-creatine (P-Cr) at the indicated time point. Bioluminescence was quantified 1157 
weekly as a measure of disease burden. Data are represented as mean ± SEM of 1158 
seven mice per cohort. p value was calculated on the latest time point using a 1159 
nonparametric Kruskall-Wallis test and Dunn’s multiple comparisons test. Kaplan-Meier 1160 
curves showing overall survival (right panel). Statistical significance determined by log-1161 
rank (Mantel-Cox) test. * and # p value ≤ 0.05 by comparison with vehicle- and Ccr-1162 
treated groups respectively. n.s, not significant. 1163 
1164 
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LEGENDS TO SUPPLEMENTARY FIGURES 1165 
 1166 
Figure S1. Effect of Evi1 overexpression on metabolism of hematopoietic 1167 
progenitor cells.  1168 
Heatmap of the top up- or down-regulated metabolites identified by steady-state 1169 
metabolism profiling in control versus Evi1-overexpressing LinLow murine bone marrow 1170 
cells. Results are presented as an absolute log2 Fold Change of Evi1 overexpression 1171 
normalized to the average empty condition. Each column for each condition represents 1172 
a technical replicate (n=3 per condition). 1173 
 1174 
Figure S2. Effect of doxycycline and GM-CSF supplementation on CKMT1 1175 
expression and sensitivity to CKMT1 depletion.  1176 
(A-B) Immunoblot (A) and relative growth (B) of TF-1 and UCSD-AML1 human cell lines 1177 
transduced with either a control (CT) or two CKMT1-directed shRNAs. * p value ≤ 0.05 1178 
calculated using a Mann-Whitney test in comparison with the shControl condition. Error 1179 
bars represent the mean ± SD of seven technical replicates. (C-D) Effect of GM-CSF 1180 
withdrawal on CKMT1 expression by immunoblot and cyclocreatine (Ccr) sensitivity in 1181 
the indicated human AML cell lines. * p value ≤ 0.05 calculated using a Mann-Whitney 1182 
test in comparison with + GM-CSF condition. Error bars represent mean ± SD of four 1183 
different EVI1 high human cell lines. n.s, not significant. (E) Immunoblot analysis of the 1184 
effect of a 10 day GM-CSF supplementation on the expression of CKMT1 in two AML 1185 
cell lines, HL-60 and U937.  1186 
Each experiment was performed at least two independent times. 1187 
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Figure S3. Effect of the modulation of EVI1 expression on RUNX1 and CKMT1 1188 
mRNA and protein levels.  1189 
(A-B) qRT-PCR for Evi1, Runx1, and Ckmt1 expression (A) and immunoblot for Evi1, 1190 
Runx1, Ckmt1 and Gapdh (loading control) (B) from LinLow, c-Kit+ murine bone marrow 1191 
cells infected with an empty or Evi1-encoding construct. (C-D) qRT-PCR for EVI1, 1192 
RUNX1, and CKMT1 expression (C) and immunoblot for EVI1, RUNX1, CKMT1, and 1193 
HSP60 (loading control) from human UCSD-AML1 cells infected with either a control 1194 
shRNA (shCT) or three EVI1-directed shRNAs (D). (A and C) * p value ≤ 0.05 1195 
calculated using Mann-Whitney test in comparison with the control (either empty for 1196 
panel A or shCT for panel C) condition. Error bars represent mean ± SD of four 1197 
technical replicates. Data are representative of at least two independent experiments. 1198 
 1199 
Figure S4. Effect of CK pathway inhibition on levels of creatinine, 1200 
guanidinoacetate, and L-arginino-succinate. 1201 
(A-B) Normalized peak areas of 13C-labeled metabolites in human UCSD-AML1 cells 1202 
infected with either shControl or two CKMT1-directed shRNAs (A), or in TF-1 human 1203 
cells treated with 3 mM cyclocreatine (Ccr) for 15h in combination with phospho-1204 
creatine (P-Cr) (B). * p value ≤ 0.05 calculated using Welch’s t-test in comparison with 1205 
the control condition. ns = not significant. Error bars represent mean ± SD of three 1206 
technical replicates. 1207 
 1208 
Figure S5. Effect of CKMT1 overexpression on mitochondria function. 1209 
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(A) Immunoblot for CKMT1 and VINCULIN (loading control) from human NB-4 and 1210 
U937 cells overexpressing a construct encoding a wild-type (WT) or a mutant (C316G) 1211 
form of CKMT1. 1212 
(B) Growth inhibition of human NB-4 and U937 cells expressing a construct encoding 1213 
either a wild-type (WT) or a mutant (C316G) form of CKMT1 and treated with increasing 1214 
concentrations of cyclocreatine (Ccr). Error bars represent mean ± SD of seven 1215 
technical replicates per dose. 1216 
(C) Intracellular ATP levels in human NB-4 and U937 AML cells expressing a construct 1217 
encoding either a WT or a mutant (C316G) form of CKMT1 and treated with 12 mM 1218 
cyclocreatine (Ccr) for 12 hours. Results represent the average of triplicate assays. * p 1219 
value ≤ 0.05 calculated using a Mann-Whitney test in comparison with the control 1220 
condition. Error bars represent mean ± SD of four technical replicates per condition. 1221 
(D) OCR of either eGFP- or wild-type (WT) CKMT1-overexpressing human U937 cells 1222 
treated with 12 mM cyclocreatine (Ccr) for 12 hours prior to measurement under basal 1223 
conditions, following sequential injections of 1 μM ATP synthase inhibitor oligomycin, 1 1224 
μM uncoupler agent FCCP, and 1 μM complex I and III inhibitors rotenone and 1225 
antimycin A. * p value ≤ 0.05 calculated using a Mann-Whitney test in comparison with 1226 
the CKMT1 WT control condition. Error bars represent mean ± SD of four technical 1227 
replicates.  1228 
Each experiment was performed at least two independent times. 1229 
 1230 
Figure S6. Top scoring genes identified by Leading Edge Analysis (A) Heatmaps 1231 
of the core cyclocreatine (Ccr)-downregulated genes that were identified by Leading 1232 
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Edge Analysis of the three functional gene set categories "Cell Stemness", "Cell Cycle" 1233 
and "Cell Differentiation” enriched by GSEA. In red are selected genes of interest 1234 
validated by qRT-PCR. Each column for each condition represents an independent 1235 
biological replicate (n=3 per condition in three individual human EVI1-positive cell lines). 1236 
(B) qRT-PCR for MYC and CCND1 expression level in indicated AML cells treated with 1237 
cyclocreatine (Ccr) for 24 hours. Error bars represent mean ± SD of four technical 1238 
replicates. * p value ≤ 0.05 in comparison with the control condition calculated using a 1239 
Mann-Whitney test. Data are representative of at least two independent experiments. 1240 
 1241 
Figure S7. Characterization of the in vivo mouse models used to study the effect 1242 
of CKMT1 depletion on disease development.  1243 
(A) Growth inhibition of wild-type (WT), N-RasG12D, or N-RasG12D + Evi1 cells treated 1244 
with increasing concentrations of cyclocreatine (Ccr). Error bars represent mean ± SD 1245 
of seven technical replicates per dose.  1246 
(B) Model of the competitive bone marrow transplantation assay developed to 1247 
characterize the toxicity of Ckmt1 depletion on normal murine progenitors using two 1248 
Ckmt1-directed shRNAs versus a control shRNA. 1249 
(C) Chimerism of CD45.1+ versus CD45.2+ murine cell populations (top panel) and 1250 
shCkmt1-expressing CD45.1+ versus shControl-expressing CD45.2+ cell populations 1251 
(bottom panel) were evaluated by FACS on the whole bone marrow at day 10 post-1252 
transplantation (n=4 mice per group). Data are representative of at least two 1253 
independent time points. 1254 
 1255 
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(D-E) Bioluminescence of human U937-Luc (D) and TF-1 CSF2+-Luc (E) cells injected 1256 
into nude mice was quantified at each indicated time point post-injection to assess 1257 
emergence of the disease. Data are represented as mean ± SEM of five mice per 1258 
group. * p value ≤ 0.05 calculated using a Mann-Whitney test in comparison with no 1259 
luciferin (no Lucif.) condition. Error bars represent mean ± SEM. At day 8 and day 10 1260 
post-injection, luciferase signal from U937 and TF-1 cells respectively, started to be 1261 
significantly detected. 1262 
 1263 
LEGENDS TO SUPPLEMENTARY TABLES 1264 
 1265 
Table S1. List of top depleted and enriched genes identified in the in vitro shRNA 1266 
screening on UCSD-AML1 and TF-1 cells. 1267 
Genes are categorized based on Normalized Enrichment Score (NES) and -log10 (p 1268 
value). Core depletion / enrichment means that genes scored in both cell lines; TF-1_ or 1269 
UCSD-AML1_ depletion / enrichment means that genes scored only in the indicated cell 1270 
line; 0 means no significant depletion or enrichment in any cell lines. 1271 
 1272 
Table S2. Cytogenetics and clinical features of patients samples used in this 1273 
study. n/a: limited patient data available, unknown: test was not done and thus data not 1274 
available. 1275 
 1276 
Table S3. Top genes significantly downregulated by cyclocreatine treatment in 1277 
TF-1, UT-7, and UCSD-AML1 cell lines. 1278 
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Significance cut-offs: Fold Change (Log2 FPKM) = -0.5, permutation p value = 0.05, 1279 
False Discovery Rate (Benjamini-Hochberg) = 0.05. Top scoring genes identified from 1280 
Leading Edge Analysis are underlined. 1281 
 1282 
Table S4. Top genes significantly upregulated by cyclocreatine treatment in TF-1, 1283 
UT-7, and UCSD-AML1 cell lines. 1284 
Significance cut-offs: Fold Change (Log2 FPKM) = 0.5, permutation p value = 0.05, 1285 
False Discovery Rate (Benjamini-Hochberg) = 0.05. 1286 
 1287 
Table S5. Table of selective gene sets enriched by GSEA in genes whose 1288 
expression was downregulated (DOWN) or upregulated (UP) by cyclocreatine 1289 
(Ccr) treatment in TF-1, UT-7, and UCSD-AML1 cell lines.  1290 
NES = Normalized Enrichment Score. Significant p value cut-off: 0.05. 1291 
 1292 
SUPPLEMENTARY METHODS 1293 
 1294 
Cell Culture 1295 
HL-60, U937, Mono-Mac-6, Kasumi-3, NB-4, and TF-1 cell lines were purchased 1296 
from the American Type Culture Collection. UT-7 and UCSD-AML1 were purchased 1297 
from DSMZ. MOLM-13 was provided by Dr. Benjamin Ebert; THP-1 and MOLM-14 cell 1298 
lines by Dr. Scott Armstrong. Identity of these three cell lines was confirmed by STR loci 1299 
profiling. All cell lines tested negative for mycoplasma. All cell lines, except MOLM-13, 1300 
TF-1, UT-7, Kasumi-3, and UCSD-AML1, were maintained in RPMI 1640 (Cellgro) 1301 
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supplemented with 1% penicillin-streptomycin and 10% fetal bovine serum (FBS, 1302 
Sigma-Aldrich) at 37 °C with 5% CO2. MOLM-13 cells were maintained in RPMI 1640 1303 
supplemented with 1% penicillin-streptomycin and 20% FBS. TF-1, UT-7, Kasumi-3, 1304 
and UCSD-AML1 were maintained in RPMI 1640 supplemented with 1% penicillin-1305 
streptomycin and 10% FBS with 20 ng per ml GM-CSF (Peprotech). The 293E cells 1306 
were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 1307 
10% fetal calf serum (FCS) (Invitrogen) and 100 units per ml penicillin/streptomycin 1308 
(Invitrogen). 1309 
Primary patient AML blasts were collected from bone marrow aspirates after 1310 
obtaining patient informed consent under a Dana-Farber Cancer Institute Internal 1311 
Review Board-approved protocol. Mononuclear cells were isolated using Ficoll-Paque 1312 
Plus (Amersham Biosciences) and red blood cells were lysed before flow cytometry 1313 
analysis. These cells were maintained in StemSpan SFEM (#09650, StemCell 1314 
Technologies Inc.) medium supplemented with 20 ng/ml IL-3 (#200-03, Peprotech), 20 1315 
ng/ml IL-6 (#200-06, Peprotech), 20 ng/ml GM-CSF (#300-03, Peprotech), 100 ng/ml 1316 
FLT3-Ligand (#300-19, Peprotech) and 100 ng/ml SCF (#300-07, Peprotech). 1317 
 1318 
Chemicals 1319 
Cyclocreatine and L-Arginine 13C6 were purchased from Sigma-Aldrich (Sigma). 1320 
Phospho-creatine was purchased from Tocris Bioscience for in vitro studies and from 1321 
Sigma-Aldrich for in vivo studies. 1322 
 1323 
Site-directed Mutagenesis 1324 
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Deletion in the CKMT1 promoter sequence and mutation into glycine of the 1325 
cysteine residue C316 required for synergistic binding of CKMT1 to its substrate were 1326 
obtained using a QuikChange XL Site-directed mutagenesis kit (Stratagene). Primers 1327 
used for this mutagenesis reaction are listed below. 1328 
Targets Mutants Primer Sequence 
CKMT1 C316G Forward GGGATACATCTTGACCGGTCCATCTAACCTGGGReverse CCCAGGTTAGATGGACCGGTCAAGATGTATCCC
CKMT1 
promoter ∆ACCACA 
Forward CCCACACCCAGTCATCTCCCCTTCACCTCACTTTAC
Reverse GTAAAGTGAGGTGAAGGGGAGATGACTGGGTGTGGG
 1329 
Creatine Kinase Activity Measurement 1330 
Creatine kinase activity was evaluated using the Creatine Kinase Activity 1331 
Colorimetric Assay Kit (Abcam) on lysates from AML cell lines (in quadruplicate, 20 µg 1332 
per replicate) spun through a 10K column (Biovision) to remove small molecules, such 1333 
as NADH that could interfere with the assay. 1334 
 1335 
Morphology Evaluation 1336 
Cytospins were prepared and stained with May-Grunwald Giemsa (Sigma-1337 
Aldrich) to evaluate cellular morphology. Images were acquired by light microscopy 1338 
under oil at 1000X magnification with an Olympus Bx41 microscope and SPOT 1339 
software. Size of freshly collected cells was evaluated using a Countess Automated Cell 1340 
Counter (Invitrogen). 1341 
 1342 
CKMT1 Promoter Reporter Assay 1343 
The - 3675 to +1 (transcriptional start site) CKMT1 promoter and all the truncated 1344 
sequences were cloned into a pEZX-LvPG04 luciferase vector (GeneCopoeia) and the 1345 
59 
 
NEG-LvPG04 (GeneCopoeia) was used as a negative control vector. Transfection 1346 
medium was replaced by fresh medium 24 hours after transfection. After 36 hours of 1347 
incubation, medium was collected for parallel bioluminescence assays of Gaussia 1348 
luciferase (GLuc) and secreted alkaline phosphatase (SEAP) using Secrete-PairTM 1349 
Dual Luminescence Assay Kit (Genecopoiea). 1350 
 1351 
Intracellular ATP Content Measurement 1352 
 ATP concentration was evaluated using the ATP Colorimetric Assay Kit 1353 
(Abcam) on lysates from AML cell lines (in quadruplicate, 150 µg per replicate) 1354 
according to the manufacturer’s instructions. The ADP/ATP Ratio Assay Kit was used to 1355 
determine ADP/ATP ratio on alive cells plated in 384-well plate format. 1356 
 1357 
Mitochondrial Activity Measurement 1358 
Oxygen consumption of intact cells was measured using an XF24 Extracellular 1359 
Flux Analyzer (Seahorse Bioscience) at the Seahorse Core Facility supervised by Dr. 1360 
William Oldham (Brigham & Women’s Hospital, Boston, MA, USA). Seahorse plates 1361 
were coated with Cell TAK (BD, 0.02 mg ml−1 in 0.1 μM NaHO3) for 20 minutes to 1362 
increase adherence of AML cells. Then, 1x106 cells were attached to the plate by 1363 
centrifugation at 1,000g, without brakes for 5 min. XF assay medium modified DMEM 1364 
was used for all experiments in the presence of 1 mM pyruvate, 5 mM glucose, and 2 1365 
mM glutamine without serum. Respiration was measured under basal conditions, in the 1366 
presence of the mitochondrial inhibitor oligomycin (1 µM) and in the presence of the 1367 
mitochondrial uncoupler FCCP (1 µM) to assess maximal oxidative capacity, and 1368 
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ultimately in the presence of 0.5 µM rotenone and antimycin A. All compounds were 1369 
diluted in the assay buffer and injected into the wells sequentially as indicated for each 1370 
experiment. Data from each time point were normalized to protein concentrations in 1371 
each well. 1372 
 1373 
Methylcellulose Assay 1374 
Colony forming assays with primary murine bone marrow cells and AML cell lines 1375 
were performed in methylcellulose-based medium MethoCult GF M3434 and ClonaCell-1376 
TCS respectively (Stem Cell Technologies). GFP-positive control or Evi1-expressing 1377 
progenitor cells and AML cell lines were seeded 1×104 cells and 0.5×103 cells per plate 1378 
in triplicate, respectively, and scored for colony formation 10 days later. The remaining 1379 
cells of the same condition were then resuspended, pooled, and washed once in PBS. 1380 
Cells were replated in triplicate under the same culture conditions as above and 1381 
colonies were scored 10 days later. Serial replating was performed a total of 4 times. 1382 
AML cell lines were replated until colony extinction. The number of colonies was 1383 
counted after MTT staining. 1384 
 1385 
Growth Assessment 1386 
To assess growth, cells were plated in a minimum of four replicates in 384-well 1387 
plates and growth was measured using CellTiter Glo (Promega) per the manufacturer’s 1388 
instructions. For assessment of cell number, cells were plated in triplicate and manually 1389 
counted with Trypan blue exclusion on the indicated days. 1390 
 1391 
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Cell Cycle Analysis 1392 
AML cells were harvested at the indicated time points, washed in PBS and fixed 1393 
in ice cold 70% ethanol for a minimum of 4 hours. Cells were then washed in PBS and 1394 
incubated in 3.3 μL of 30 mg/ml RNase A (Sigma-Aldrich) and 15 μL of 1 mg/ml 1395 
propidium iodide (Sigma- Aldrich) for 30 minutes. For each condition, 10 000 cells were 1396 
then analyzed on a BD FACSCanto II HTS. Data analysis was completed using FlowJo 1397 
software. 1398 
 1399 
Apoptosis Assay 1400 
Cell death was assessed using flow cytometric analysis of Annexin V and 1401 
Propidium Iodide staining according to the manufacturer’s instructions (eBioscience). 1402 
For each condition, 10 000 cells were analyzed on a BD FACSCanto II HTS. Data 1403 
analysis was completed using FlowJo software. 1404 
 1405 
RNA Extraction and qRT-PCR Analysis 1406 
RNA was extracted from cells with an RNeasy Kit (Qiagen). Primers and probes 1407 
for each target gene were obtained from Applied Biosystems. The list of probes and 1408 
their references is available below. Data were collected in technical quadruplicate, 1409 
analyzed using the ∆∆CT method, and plotted as percentage of transcript compared to 1410 
the negative control condition. 1411 
 1412 
Targets Species References Manufacturer 
CCND1 Homo Sapiens Hs00765553_m1 ThermoFischer Scientific
CKMT1 Homo Sapiens Hs000179727_m1 ThermoFischer Scientific
EVI1 Homo Sapiens Hs01115405_m1 ThermoFischer Scientific
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MYC Homo Sapiens Hs00905030_m1 ThermoFischer Scientific
RPL13A Homo Sapiens Hs04194366_g1 ThermoFischer Scientific
RUNX1 Homo Sapiens Hs01021970_m1 ThermoFischer Scientific
Ckmt1 Mus Musculus Mm00438216_m1 ThermoFischer Scientific
Evi1 Mus Musculus Mm00514810_m1 ThermoFischer Scientific
Rpl13a Mus Musculus Mm01612986_gH ThermoFischer Scientific
 1413 
In Vivo Transplantation 1414 
The Massachusetts Institute of Technology Committee on Animal Care reviewed 1415 
and approved all mouse experiments described in this study. Ex vivo metabolomics 1416 
experiments were performed on bone marrow progenitor cells harvested from 4-week-1417 
old C57BL/6 male donor mice (The Jackson Laboratory) which were primed with 1418 
intraperitoneal injection of 5′-fluorouracil (150 mg/kg) and subsequently sacrificed after 7 1419 
days by CO2 asphyxiation. Bone marrow was harvested from femur, tibia and humerus, 1420 
and red blood cells were lysed (Red Blood Cell Lysis, RBCL buffer, Sigma). The 1421 
LineageLow cell fraction was sorted from the total bone marrow following exclusion of 1422 
CD5+, CD127+, and CD45R+ cell populations using FACS Aria (BD Biosciences). These 1423 
sorted cells were then resuspended in transplant medium made with 20 ng/ml IL-3 1424 
(#213-13, Peprotech), 20 ng/ml IL-6 (#216-16, Peprotech), 100 ng/ml FLT3-Ligand 1425 
(#250-31L, Peprotech) and 100 ng/ml SCF (#250-03, Peprotech) in StemSpan SFEM 1426 
(#09650, StemCell Technologies Inc.), and transduced with either empty or Evi1 GCDN-1427 
IRES-GFP vectors by two rounds of spin-infection, at 12 hour intervals. For each spin-1428 
infection, plates were coated with 50 μg/mL retronectin (Takara) per the manufacturer’s 1429 
instructions and fresh viral supernatant was added onto each retronectin-coated well 1430 
before spinning for two hours at 2000g at 32 °C to allow virus binding to the retronectin. 1431 
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10×106 cells in 3 mL transplant media containing 5 μg/mL polybrene (Sigma) and 7.5 1432 
mM HEPES buffer (Sigma) were then seeded into each of these wells and centrifuged 1433 
for 4 hours at 1800g to promote cell transduction. After two days, cells were sorted 1434 
based on expression of the GFP fluorescent protein and then used as previously 1435 
described for metabolomics experiments, or methycellulose assays. 1436 
 1437 
For in vivo dependency experiments using the NrasG12D (mutant 6606) and 1438 
NrasG12D + Evi1 (mutant 6613) transplantable murine cells, B6129SF1/J mice were 1439 
purchased from The Jackson Laboratory. Sample size was chosen in light of the fact 1440 
that these in vivo models were historically highly penetrant, aggressive, and consistent. 1441 
No specific statistical method was used to determine sample size. In addition, all control 1442 
groups were followed until time to necessary sacrifice determined based on: a 10 to 20-1443 
fold increase in proportion of circulating leukemic blasts compared to non-transplanted 1444 
mice, weight loss, and hunched posture. All mice were randomized to treatment. 1445 
Animals were excluded from the study if any signs of distress were observed without 1446 
clinical signs of leukemia: absence of leukemic blasts in bone marrow, spleen, and 1447 
blood. None of our animals were excluded based on these criteria. Blinded observers 1448 
visually inspected mice for obvious signs of distress, such as loss of appetite, hunched 1449 
posture, and lethargy. Approximately 5 × 106 NrasG12D and NrasG12D + Evi1 bone 1450 
marrow-derived murine primary cells were infected with a doxycycycline-inducible 1451 
TRIPZ-Venus vector encoding either control or two Ckmt1-directed shRNAs according 1452 
to the previously described retronectin-based protocol, and were tail vein injected as a 1453 
secondary transplant into sublethally irradiated (600 cGy) 6-week-old male B6129SF1/J 1454 
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mice. After two weeks, mice were sacrificed and the NrasG12D and NrasG12D + Evi1 cells 1455 
infected with TRIPZ-Venus vector were harvested from femur, tibia and humerus, and 1456 
red blood cells were lysed. The venus-positive NrasG12D and NrasG12D + Evi1 cell 1457 
fractions were sorted from the whole bone marrow, and 0.2x106 cells were injected into 1458 
tertiary recipients for the beginning of the experiment. For in vivo knockdown 1459 
experiments, level of Ckmt1 extinction was evaluated by western blot. WBC was 1460 
measured using a Hemavet Automated Veterinary Analyzer on whole blood collected by 1461 
retro-orbital bleeding.  1462 
 1463 
In vivo chimerism experiments were performed using CD45.1+ and CD45.2+ bone 1464 
marrow progenitor cells harvested from 4-week old CD45.1+ B6.SJL-Ptprca Pepcb/Boy 1465 
and CD45.2+ C57BL/6 male donor mice respectively (The Jackson Laboratory) which 1466 
were primed with intraperitoneal injection of 5′-fluorouracil (150 mg/kg) and 1467 
subsequently sacrificed after 7 days by CO2 asphyxiation. Bone marrow was harvested 1468 
from femur, tibia and humerus, and red blood cells were lysed (Red Blood Cell Lysis, 1469 
RBCL buffer, Sigma). The LineageLow cell fraction was sorted from the total CD45.1+ 1470 
and CD45.2+ bone marrow and the sorted cells were then resuspended in transplant 1471 
medium made with 20 ng/ml IL-3 (#213-13, Peprotech), 20 ng/ml IL-6 (#216-16, 1472 
Peprotech), 100 ng/ml FLT3-Ligand (#250-31L, Peprotech) and 100 ng/ml SCF (#250-1473 
03, Peprotech) in StemSpan SFEM (#09650, StemCell Technologies Inc.). CD45.2+ and 1474 
CD45.1+ progenitor cells were transduced with a GFP-expressing shCT or two different 1475 
GFP-expressing Ckmt1-directed shRNAs respectively by a 12-hour spin-infection using 1476 
retronectin-coated plates as previously described. After spin-infection, infected CD45.1+ 1477 
65 
 
and CD45.2+ progenitors were mixed at equal density (5x106 cells for each fraction) 1478 
before tail vein injection into lethally irradiated (2 x 500 cGy at 3-hour interval) 4-week 1479 
old C57BL/6 recipient mice. Chimerism was evaluated using specific anti-CD45.1 and 1480 
anti-CD45.2 antibodies (reference of antibodies listed in the table above) and the 1481 
proportion of shCT and shCkmt1 GFP cells in each of these fractions was assessed by 1482 
flow cytometry. 1483 
 1484 
TF-1 cells were transduced with a lentiviral vector encoding for human GM-CSF 1485 
(CSF2) in order to promote their growth in vivo independently of exogenous GM-CSF. 1486 
U937 and TF-1 CSF2+ cells were transduced with the pMMP-LucNeo retrovirus and 1487 
selected with neomycin at 1 mg/ml. After selection, luciferase-expressing U937 and TF-1488 
1-CSF2+ cells were then transduced with retroviral doxycycline-inducible TRMPVIR 1489 
constructs either control or indicated targeting shRNAs. 0.5x106 U937 and 1.5x106 TF-1 1490 
CSF2+ cells were subsequently injected via tail vein into 6- to 8-week-old nude mice 1491 
(Taconic) and mice were imaged weekly on an IVIS Spectrum (Caliper Life Sciences) to 1492 
assess the bioluminescence level. At a significant detection level of bioluminescence 1493 
(Supplementary Figure S7B and 7C), mice were treated daily by i.p injection with 20 1494 
μg/ml doxycycline to quickly induce hairpins expression and drinking water was 1495 
supplemented with 1 mg/ml doxycycline and 5% sucrose throughout the experiment. 1496 
 1497 
The purity of cyclocreatine used for in vivo work was higher than 99% by NMR. 1498 
Two weeks post-injection, mice were treated daily by oral gavage with 0.2 g/kg 1499 
cyclocreatine (22% hydroxypropyl-β-cyclodextrin in sterile water; in 200 μl) for two 1500 
66 
 
weeks and drinking water was supplemented with cyclocreatine – at a sufficient 1501 
concentration to ensure a consumption of 1g/kg/day cyclocreatine – and 5% sucrose 1502 
throughout the experiment. For in vivo rescue experiments, mice were treated twice 1503 
daily with intraperitoneal injection 0.4 g/kg phospho-creatine (in sterile water; in 150 ul) 1504 
for two weeks and drinking water was supplemented at the same amount as 1505 
cyclocreatine throughout the experiment. 1506 
 1507 
Statistical Analysis 1508 
Statistical analysis was done using Microsoft Excel, Prism 5.03 (GraphPad) or indicated 1509 
software for more dedicated analysis. Statistical significance was determined by 1510 
unpaired Student’s t-test after testing for normal distribution. For samples with 1511 
significantly different variances, Welch’s correction was applied. Samples with non-1512 
normal distribution (with the assumption of no Gaussian distribution of the group) were 1513 
analyzed using a nonparametric Mann-Whitney test, and the level of significance 1514 
(alpha) was always set at 0.05. For comparison of three or more groups, nonparametric 1515 
Kruskall-Wallis and Dunn’s multiple comparisons tests were used, and the level of 1516 
significance was always set at 0.05. 1517 
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